Evaluation of hepatoprotective effects of Boesenbergia Rotunda and Curcuma Longa rhizomes extracts in thioacetamide-induced liver damage in rats / Suzy Munir Salama Fanous by Suzy Munir, Salama Fanous
EVALUATION OF HEPATOPROTECTIVE EFFECTS OF 
BOESENBERGIA ROTUNDA AND CURCUMA LONGA RHIZOMES 
EXTRACTS IN THIOACETAMIDE-INDUCED LIVER DAMAGE IN 
RATS  
 
 
SUZY MUNIR SALAMA FANOUS 
 
 
THESIS SUBMITTED IN FULFILMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
 
 
FACULTY OF MEDICINE 
UNIVERSITY OF MALAYA 
KUALA LUMPUR 
 
 
 
2013 
UNIVERSITI MALAYA 
i 
 
  
 
ii 
 
ABSTRACT 
Researchers focused on developing traditional therapies as pharmacological medicines 
to treat liver cirrhosis that is accompanied by abnormality in liver functions. This study 
evaluated the mechanisms of hepatoprotective activity of Boesenbergia rotunda and 
Curcuma longa rhizome ethanolic extract on liver damage induced by thioacetamide in 
rats.  
The crude extracts of Boesenbergia rotunda and Curcuma longa were tested for acute 
toxicity and antioxidant properties evaluated by 2,2-diphenyl-1-picrylhydrazyl (DPPH), the 
antioxidant power of reducing iron (FRAP) and total phenolic content (TPC) The 
hepatoprotective effect of the plant extracts was evaluated in a rat model of thioacetamide-
induced liver damage over 8 weeks. Male Sprague Dawley rats were intraperitonealy 
injected with 200 mg/kg thioacetamide (TAA) 3 times/week for 8 weeks and daily oral 
administration of 250 mg/kg and 500 mg/kg for 8 weeks. Silymarin was used as a reference 
drug that was orally administered to the animals at a daily dose of 50 mg/kg. At the end of 
the 8 weeks, liver damage was evaluated by weight changes, liver gross and histopathology 
and biochemical measurements of liver parameters, (AP, ALT, AST, GGT and LDH), 
prothrombin time ratio, total protein, albumin and bilirubin and lipid profile. The degree of 
liver fibrosis was measured by Masson’s Trichrome staining. Hepatic cytochrome P450 
2E1, Matrix metalloproteinase (MMP-2 and MMP 9) and tissue inhibitor of 
metalloproteinase (TIMP-1) were measured. Serum levels of transforming growth factor 
TGF-β1, nuclear transcription factor NF-ĸB, pro-inflammatory cytokine IL-6 and caspase-3 
were evaluated. Stress due to oxidation was evaluated by liver malondialdehyde, 
nitrotyrosine and urinary hydroxyl deoxyguanosine levels. The hepatoprotective activity of 
B. rotunda and C. longa extracts was evaluated through the liver level of antioxidant 
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enzymes superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx). 
Protein expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins in the animal 
blood sera was determined and confirmed by immunohistochemistry of Bax, Bcl-2 proteins 
and proliferating cell nuclear antigen (PCNA).  
Panduratin A and Germacrone compounds of B. rotunda and C. longa rhizomes 
respectively were tested for their cytotoxicity and protective activity against TAA-induced 
oxidative damage in embryonic normal liver cell line WRL-68. The compounds were 
isolated from the ethanolic crude extracts by Column chromatography, thin layer 
chromatography and high performance liquid chromatography and their mass was 
determined by Liquid Chromatography Mass Spectrometry (LCMS) (m/z = 407.22 for 
Panduratin A and 219.17 for Germacrone). The hepatoprotective activity of the isolated 
Panduratin A was evaluated in vivo in a similar rat model for a period of 4 weeks using 3 
different doses 5, 10 and 50 mg/kg. The effect of Panduratin A on hepatic stellate cells 
(HSCs) activity was measured by alpha-smooth muscle actin staining.  
B. rotunda and C. longa treatment improved liver histopathology, 
immunohistochemistry and biochemistry, triggered apoptosis, inhibited serum cytokines, 
extracellulat matrix proteins and hepatocytes proliferation, but C. longa had no impact on 
hepatic CYP2E1, MMP-2 or TIMP-1 levels. Moreover, Panduratin A showed significant 
improvement in the liver biochemistry, histopathology and inhibited HSCs activity.  
The development of liver fibrosis can be attenuated by the antioxidant and anti-
inflammatory activities of C. longa and B. rotunda ethanolic extracts and its active 
compound Panduratin A while the normal status of the liver can be preserved.  
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ABSTRAK 
Kebelakangan ini, para penyelidik memberi tumpuan bagi membangunkan terapi 
tradisional sebagai ubat farmakologi untuk merawat sirosis hati yang menyebabkan 
gangguan fungsi hati. Kajian ini bertujuan menilaik mekanisme hepatoprotif oleh ektrak 
etanol rizom Boesenbergia rotunda dan Curcuma terhadap thioacetamide yang 
menyebabkan sirosis hati dalam tikus. 
Ekstrak mentah B. rotunda dan C. longa telah diuji ketoksikannya serta ciri antioksidan 
telah dinilai oleh DPPH, penurunan kuasa antioxidan ferric (FRAP) dan jumlah kandungan 
fenolik (TPC).  Kesan hepatoprotectif ekstrak tumbuhan telah diukur menggunakan model 
tikus terhadap kerosakan hati oleh thioacetamide selama lebih 8 minggu.   Tikus jantan 
Sprague Dawley telah diberi suntikan intraperitoneal sebanyak 200 mg / kg TAA 3 kali / 
minggu selama 8 minggu dan pengambilan secara oral sebanyak 250 mg / kg dan 500 mg / 
kg selama 8 minggu. Silymarin telah digunakan sebagai dadah rujukan telah diberikan 
secara oral kepada haiwan tersebut dengan dos harian sebanyak 50 mg / kg.  Pada akhir 
minggu ke-8, kerosakan hati telah dinilai oleh perubahan berat, pembengkakkan hati  
pengukuran histopatologi dan biokimia parameter hati, (AP, ALT, AST, GGT dan LDH), 
nisbah masa prothrombin, jumlah protein, albumen dan bilirubin dan profil lipid. Tahap 
fibrosis hati telah diukur oleh pewarnaan Masson Trichrome. Hepatik Cytochrome 2E1 
P450, Matrix metalloproteinase (MMP-2 dan MMP 9) dan perencat tisu metalloproteinase 
(TIMP-1) telah diukur. Tahap serum pengubah faktor pertumbuhan TGF-β1, faktor 
transkripsi nuklear NF-ĸB, sitokin pro-inflamasi IL-6 dan caspase-3 telah dinilai. Tekanan 
oksidatif telah diukur oleh malondialdehida, urinari 8-hidroksiguanosin dan tahap 
nitrotirosin. Aktiviti protektif oleh ekstrak B. rotunda dan C. longa telah dinilai melalui 
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tahap enzim antioksidan pada hati (SOD, CAT dan Gpx). Ekspresi protein pro-apoptotik 
Bax dan anti-apoptotik Bcl-2 protin dalam serum darah haiwan telah ditentukan dan 
disahkan oleh Immunohistokimia Bax, Bcl-2 protin dan sel membiak antigen nuklear 
(PCNA). Panduratin A yang terdapat pada rizom B. rotunda dan sebatian Germacron yang 
terdapat pada rizom C. longga masing-masing telah diuji untuk ujian sitotosik dan aktiviti 
protektif terhadap TAA peyebabkan kerosakan oksidatif dalam embrio sel hati normal 
WRL-68.  Sebatian yang terdapat dalam ekstrak etanolik mentah telah dipisahkan secara 
kromatografi turus kromatografi (CC) kromatografi lapisan nipis (TLC), kromatografi 
cecair berprestasi tinggi (HPLC) dan jisim molekul sebatian telah ditentukan oleh 
kromatografi cecair-spektrometri jisim (LC-MS). Aktiviti hepatoprotektif oleh Panduratin-
A tulen telah dinilai dalam ujian in-vivo dalam model tikus yang sama untuk tempoh 4 
minggu menggunakan 3 dos berbeza 5, 10 dan 50 mg / kg. Kesan Panduratin-A ke atas sel 
hepatik stallete (HSCs) telah diukur oleh pewarnaan actin otot alfa-licin. Rawatan extrak 
B.Rotunda dan C. longga memberi kesan memberangsangkan terhadap  histopatologi hati, 
immunohistokimia dan biokimia, mencetuskan apoptosis, menghalang sitokin serum, sel 
luaran matriks protin dan proliferasi hepatosit, tetapi C. longa tidak mempunyai kesan ke 
atas tahap hepatik CYP2E1, MMP-2 atau TIMP-1. Selain itu, Panduratin A menunjukkan 
peningkatan yang ketara dalam biokimia hati, histopatologi dan menghalang aktiviti HSCs. 
Perkembangan sirosis hati boleh direncat oleh aktiviti antioksidan dan anti-inflamasi 
oleh ekstrak etanolik C. longa dan B. rotunda dan dengan sebatian Panduratin A serta 
memulihara ke status normal. 
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CHAPTER I 
INTRODUCTION 
1.1. Introduction 
The liver is the largest organ within human body, it performs a variety of functions such 
as bile secretion, detoxification, and metabolism of carbohydrate food, necessary protein 
and fats, transformation of food nutrients into essential blood vessels components, storing 
vitamins, and minerals and maintaining hormone balances. The liver organ makes factors 
that help the individual defense mechanisms and eliminates bacteria from the blood 
(Nemeth et al., 2009). 
Liver diseases are the circumstances that cause injury or inflammation of the liver and 
impacts liver functions. Liver diseases can be classified to different groups. Factors like 
infections or contact with medication like paracetamol or toxins like alcohol, or viruses like 
hepatitis B and hepatitis C may affect liver functions in obstructions, inflammations, 
pathological tissue changes, scarring damage and liver failure. Liver fibrosis and its end-
stage cirrhosis signify a large worldwide medical care problem, according to the National 
Institutions of Health; cirrhosis is the twelfth major cause of loss of life. Liver fibrosis is 
the last stage in many liver injuries and cirrhosis is the last stage in liver fibrosis and all 
chronic liver diseases major in the development of nodules that change the hepatic function 
and prevent the blood flow (Pinzani et al., 2011). Liver damage due to various toxicants 
such as certain chemotherapeutic drugs, thioacetamide, CCl4, ethanol, is well-studied. 
Thioacetamide (TAA) triggered hepatotoxicity in experimental animals for the research of 
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hepatoprotective outcomes. The induction of liver cirrhosis in experimental animals by 
prolonged exposure of TAA results in clear changes in the histology and biochemistry 
appearing like human liver cirrhosis (Zimmermann et al., 1992).  
Liver cirrhosis was first presented in 1819 by Laennec (Roguin, 2006). It resulted from 
the Ancient term scirrhus and is used to explain the yellow-colored of the liver seen at 
autopsy. Cirrhosis affects an incredible number of sufferers globally. Due to serious liver 
fibrosis, the overall problem of liver diseases is constantly on the flourish, challenging and 
increasing in social and economic cost. Cirrhosis has previously been considered as the 
level at which fibrotic liver became permanent however, these days, strong facts indicate 
that fibrosis and even cirrhosis is reversible by reducing the cause of the disease in 
experimental animals, which provide vital facts to the actual procedure (Friedman et al., 
2006). 
In spite of pharmacological drugs advances, they lack efficiency, relatively costly and 
have unfavorable adverse reactions (Stickel & Schuppan, 2007). Treatment options of liver 
diseases as chronic hepatitis, cirrhosis and fatty liver are still problematic. Medical 
professionals and patients are in need of efficient treatment solutions with a low occurrence 
of side-effects. Therefore, an alternative treatment is required to treat these disorders. For 
centuries plants have formed the basis of conventional medicinal practices techniques that 
provide human with new remedies. Folk medicine in various cultures had been 
comprehensively documented. These plant-based techniques continue to play an essential 
role in health care of many nations and according to World Health Organization, 80% of 
the patients of the world consume herbal medicine for their disease (Gurib-Fakim, 2006). 
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The use of traditional medicine in treating liver diseases has long history starting with the 
Ayurvedic therapy (the ancient Native Indian system) and increasing to the European, 
Chinese and other systems of conventional medicinal practices. Large number of plants 
with nearly 160 phyto-constituents from 101 herbs has been reported for their 
hepatoprotective activities (Saleem et al., 2010). With the development of chromatography 
and spectroscopy techniques, Malaysian herbal medicines have advanced and became safe 
for human use. These new techniques have remarkable effect on the analysis of the active 
ingredients of herbal medicines (Jantan, 2004). 
Among the well recorded hepatoprotective plants is Silybum marianum (milk thistle) 
since its seed extract silymarin has been stated to possess hepatoprotective activity that was 
verified in many in vivo and in vitro researches (Pradhan & Girish, 2006). Also it has been 
revealed to prevent the liver injuries caused by various drugs via its anti-inflammatory, 
anti-lipid peroxidative, antioxidative, antifibrotic, and immuno-modulatory actions (Cragg 
& Newman, 2005). Many therapeutic herbs were known to improve the activity of the 
immune function through their strong control of cytokines that are released in response to 
injury stimulating elements, natural inflammation related reactions, cell growth, 
angiogenesis, and repair procedures (Spelman et al., 2006). The root extracts of two types 
of the traditional Chinese herbs Paeonia lactiflora and Astragalus membranaceus were 
found to acquire immuno-modulatory hepatoprotective activity via inhibition of pro-
inflammatory cytokines (Sun et al., 2008). 
Due to the serious role played by oxidative stress in the occurrence of liver 
cirrhosis, therefore, in the past few years the therapeutic herbs have been examined for their 
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anti-oxidants and toxic scavenging actions as an organic source of anti-oxidants. They were 
assumed for their health, safety and healing value to substitute the artificial anti-oxidants 
that have been limited due to their health hazards and unwanted toxicities. Plants produced 
organic anti-oxidants mainly are in the form of phenolic substances as, flavonoids and 
tocopherols, vitamin C and carotenoids which were thought to scavenge free radicals (Ali 
et al., 2008). Many patients have been treated by antioxidants. For example, in a recent 
clinical trial, 44% of patients having chronic HCV showed normal liver enzymes when 
treated in combination with antioxidant therapy and 36.1% showed histological 
improvement (Melhem et al., 2005). Several medicinal plants have been used worldwide. 
Herbal therapy such as Chinese herbal medicines and curcumin extracted from turmeric, 
have been used to treat liver diseases (Bruck et al., 2007).  
In this study, we will assess the hepatoprotective activity of Boesenbergia rotunda and 
Curcuma longa ethanolic extracts against liver cirrhosis induced by thioacetamide in 
Sprague Dawley rats by determining the presence of antioxidant in the plant extracts along 
with morphological, serum biochemical and histopathological changes. 
 
1:2 Objectives 
1.2.1. General 
To evaluate the hepatoprotective activity of B. rotunda and C. longa rhizomes crude 
extracts in vivo and Panduratin A an active compound from B. rotunda rhizomes in vivo 
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and in vitro against TAA-induced liver injury. Also to study the possible mechanism of the 
in vivo hepatoprotective activity of B. rotunda and C. longa rhizomes crude extracts. 
1.2.2. Specific 
1. To determine the in-vitro antioxidant effects of ethanolic extracts of B. rotunda and 
C. longa rhizomes. 
2. To determine the acute toxicity study and to investigate the preventive effects of 
ethanolic extracts in TAA-induced liver cirrhosis in rats by biochemical and 
histological analysis. 
3. To isolate Panduratin A from B. rotunda and germacrone from C. longa ethanolic 
extracts and to determine the protective effects against in-vitro TAA cytotoxicity in 
WRL-68 cell line. 
4. To evaluate the in-vivo hepatoprotective activity of Panduratin A in TAA-induced 
liver injury in rats. 
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CHAPTER II 
LITERATURE REVIEW 
2.1. The Liver 
2.1.1 Gross Anatomy of the Liver 
 Inside the human body, the liver is considered the largest gland in the human body. 
It is reddish brown in colour constitutes approximately 1400 – 1600 g in adult male 
(Akshatha, 2011). The normal liver occupies the right upper quadrant extending from the 
fifth intercostals space in the mid-clavicular line down to the right costal margin (Block, 
2011). The visceral peritoneum almost covers the liver, which is completely covered by 
dense connective tissue layer. 
The liver is divided into two lobes right and left that with falciform ligament 
separates between them from the anterior side and by ligamentum teres from the inferior 
side (Figure 2.1). The size of the right is bigger 6 times more than the left lobe. The right 
lobe is divided into two minor subdivisions, the quadrate and caudate lobes (Sherlock & 
Dooley, 2002).  
The liver supplies blood from two sources, the portal vein which receives 75% - 
80% and the hepatic artery which receives 20% - 25% of the cardiac output. The portal 
vein and the hepatic artery are divided into branches that carry the blood to the lobules, and 
then flows through sinusoids (Cunningham & Van Horn, 2003) 
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 Figure.2.1: Diagram showing anatomy of the liver. (Agur & Dalley, 2008). 
 
2.1.2 Histology of the Liver 
 The liver is formed of bile canaliculi, parenchyma cells called hepatocytes, and 
hepatic vessels called sinusoids. Hepatic cells are specialized epithelial cells arranged in 
plates of one cell thick; they form about 80% of the liver volume and perform many 
functions endocrine, secretory and metabolic functions. Bile canaliculi are fine ducts 
spreading between hepatic cells and collect the bile produced by hepatocytes. Hepatic 
sinusoids are permeable blood capillaries found between the plates of hepatic cells 
receiving oxygenated blood from the hepatic artery branches and nutrients content of the 
deoxygenated blood from hepatic portal vein branches, and then pass the blood to a central 
vein (Tortora & Derrickson, 2009). 
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 The hepatocytes, bile duct system and hepatic sinusoids can be functionally and 
anatomically organized in two different acceptable models: 
2.1.2.1. Hepatic Lobule 
The liver lobes composed of many small lobules defined as the classic lobule according 
to Kiernan (Preedy & Watson, 2007). The lobule is generally hexagonal composed of 
joined hepatocyte plates with endothelium lined sinusoids separating between them. The 
centrolobular vein crosses each lobule. This model represents the functional unit of the 
liver (Tortora & Derrickson, 2009). The portal vein, hepatic artery, the bile canaliculi and 
the connective tissue which surrounds them, constitute the portal triads and found at the 
angles of the hexagon (Tortora & Derrickson, 2009). 
2.1.2.2. Hepatic Acinus 
Recently, scientists accepted this structural and functional unit of the liver that includes 
portions of two neighboring hepatic lobules. Hepatocytes in the hepatic acinus are grouped 
into 3 zones based on the blood supply. Zone 1 is called the peripheral zone (periportal 
zone) as it is situated near the portal tract, zone three surrounds the vena centrolobularis 
(centrilobular zone), while zone 2 (midzonal) represents the liver parenchyma and 
situated in between zones one and three (Koek et al., 2007). The blood enters zone one 
first, and then flows through the second and the third zones before leaving the liver. Each 
zone has a specific function. Blood rich in oxygen and nutrients reaches the hepatocytes in 
zone 1, so many synthetic processes occur in this zone such as albumin production. These 
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are the first cells which take up glycogen after a meal and store it as glycogen and break 
down the stored glycogen during fasting. When the bile duct is obstructed or the liver is 
exposed to toxins, zone 1 cells are the first ones which show morphological changes 
(Tortora & Derrickson, 2009). Hepatocytes in zone 3 are very sensitive to toxins, while 
those in zone 2 have intermediated structure and function between those cells of zone 1 and 
3 (Tortora & Derrickson, 2009). (Figure 2.2) 
 
Figure.2.2: Diagram showing two Hepatic Acini showing Portal Tract (P), Central Vein 
(CV), Terminal Hepatic Venule (THV), Periportal zone (1), Intermediate zone (2) and 
Centrilobular zone (3) (Tortora & Derrickson, 2009).  
 
2.1.3 Hepatic Microstructure 
 Hepatocytes are polyhedral cells contain well-developed organelles. The rough 
endoplasmic reticulum synthesizes proteins as plasma proteins, while the smooth 
endoplasmic reticulum contains microsomes that play a role in toxin metabolism (e.g. 
drugs, some carcinogens and chemicals such as thioacetamide), as well as cholesterol and 
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bile acid synthesis. Peroxisomes perform oxidative reactions using molecular oxygen, 
involve in the fatty acids oxidation and participate in the metabolism of alcohol.  
Mitochondria are numerous and represent the site of oxidative phosphorylation and energy 
production. Their number, size and enzymatic properties depend on the position of cell 
within the hepatic acinus. Lysosomes contain scavenging enzymes besides its role in 
deposition of iron, lipofuscin, bile pigments and copper. Golgi apparatus plays a role in 
secretion of bile acids and albumin (Solter, 2005). 
 Endothelial cells are fenestrated cells lining the sinusoids. They allow the passage 
of large protein molecules and prevent the passage of blood cells and some chylomicrons to 
the perisinusoidal space. In addition, they share with macrophages in scavenging 
macromolecules. 
 Kupffer cells are special macrophages having phagocytic function located on the 
walls of sinusoids and contain lysosomes to break down phagocytized bacteria. They are 
responsible for clearing antigen-antibody complexes from blood (Solter, 2005). 
 Hepatic stellate cells (Ito cells) are found between the endothelial lining of 
sinusoids and the hepatocytes in the space of Disse. In quiescent state, they store vitamin 
A, but on stimulation, they produce collagen fibers and extracellular matrix that is 
responsible for liver fibrosis then cirrhosis (Dancygier, 2010). They are considered as a 
major regulator of normal liver homeostasis (Dancygier, 2010). 
 Pit cells are large granular lymphocytes found within the lumen of sinusoids 
adjacent to kupffer cells. They have natural killer activity, so they play a role as antitumor 
and antiviral defense (Nakatani et al., 2004). 
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2.1.4 Biochemical Functions of the Liver 
Inside the human body, the liver represents an important regulator (Koek, et al., 
2007). It is a distinctive organ which functions as a metabolic and biochemical 
transformation factory (Bacon, 2006). It is essential in maintaining the homeostasis via 
processing carbohydrates, amino acids, lipids and vitamins; metabolism of toxins and 
cholesterol; production of clotting factors and storage of glycogen (Heidelbaugh & 
Bruderly, 2006). 
The liver receives substances contained in the blood after being absorbed or 
secreted by the gastrointestinal organs including the stomach, pancreas, spleen, and the 
intestine via the hepatic portal vein (Standring, 2008). Through the hepatic artery, the liver 
receives oxygenated blood. The substances that enter the liver are then modified or re-
synthesized completely into new chemicals which are taken back to the blood or to bile to 
be excreted.  
 
2.1.4.1. Excretory Function 
Organic anions such as bilirubin and bile acids found in the sinusoidal blood are 
extracted, biotransformed and excreted into bile or urine. Haemoglobin metabolism results 
in the formation of bilivirdin by the action of heme oxygenase and then converted into 
bilirubin. It is water insoluble, so it is transported in blood attached to serum albumin as 
unconjugated bilirubin. These organic anions can be assessed by measuring their 
concentration in blood plasma by special tests (Dancygier, 2010).  
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 2.1.4.2. Synthetic Function 
About 48 g of protein is synthesized daily by the liver (Marieb & Hoehn, 2007). The 
most constituent protein in the blood plasma is Albumin. It is responsible for maintaining 
colloidal osmotic pressure (oncotic pressure) in vascular and extracellular spaces, 
transporting phospholipids, free fatty acids, amino acids, metallic ions, drugs, bilirubin and 
hormones (Marieb & Hoehn, 2007). Toxins and alcohol inhibit synthesis of albumin in the 
liver, so its concentration decreases in the plasma when the liver is injured. Alpha-1 
antitrypsin is a protein that inhibits leukocyte elastase and protects the tissue from 
enzymes released by inflammatory cells. Its concentration in plasma decreases in liver 
diseases. Transthyretin is synthesized mainly in the liver to transport thyroxine and 
retinol. All clotting factors and their inhibitors are synthesized in the liver (Mandato et al., 
2005). Liver diseases inhibit the formation of Transthyretin in the liver. The concentration 
of a number of proteins changes as a response to the injury of the liver tissue or viruses. 
The synthetic ability of the liver can be detected by prothrombin time (PT) as it depends on 
the ability of the liver to produce clotting factors. The degree of liver failure can be 
detected by the degree of prolongation of PT (Marieb & Hoehn, 2007).  
 
2.1.4.3. Metabolic Function 
The liver plays an important role in carbohydrate metabolism. In strenuous activities, 
glycogen is degraded into glucose (glycogenolysis). Hormones and genes as recently 
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reported control carbohydrate metabolism (Ptitsyn et al., 2006). In fat metabolism, the 
liver oxidizes fatty acids to supply energy, synthesize cholesterol, phospholipids and 
lipoproteins, and synthesize fats from carbohydrates and proteins. 
In protein metabolism, hepatocytes de-aminate amino acids to be used in ATP 
production, or converting them into carbohydrates or fats (Tortora & Derrickson, 2009). 
The removed ammonia from de-aminated amino acids is converted into less toxic urea, 
which is excreted in urine. The liver keeps constant equilibrium between cellular amino 
acids and proteins in cells and cellular proteins. In both acute and chronic liver diseases, 
serum ammonia rises above normal levels (Tortora & Derrickson, 2009). 
 
2.1.4.4. Exocrine Function 
Exocrine function of the liver is represented in bile secretion. Hepatocytes secrete daily 
about 500 ml of bile into biliary canaliculi. Bile is composed of inorganic electrolytes, 
water in addition to some solutes such as sodium and potassium salts (Marieb & Hoehn, 
2007). Secretion of bile results from excretion of bile pigments, steroids, cholesterol and 
some drugs.  Therefore, patients of jaundice have high cholesterol as well as alkaline 
phosphatase blood level. 
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2.1.4.5. Storage Function 
Vitamin A, B12, D, E and K are stored in large quantities in hepatic stellate cells 
(Marieb & Hoehn, 2007). Also the liver stores minerals (iron and copper) which are 
released from the liver when needed by the body. 
 
2.1.4.6. Drug and Xenobiotics’ Processing 
Xenobiotics are toxic substances to the body such as alcohol and drugs. The body 
eliminates most of these substances that are water-soluble xenobiotics through the kidneys. 
Some of these substances are secreted such as penicillin; erythromycin and sulfonamides 
are secreted into bile (Tortora & Derrickson, 2009). The liver metabolizes lipophylic 
xenobiotics by two kinds of biochemical reactions. The first phase of reactions involves 
hepatic cytochrome P450 enzymes which metabolize many different drugs. In phase II 
reactions, a big molecule is attached to the substance to make it less lipophylic and more 
water soluble to be easily excreted by the body. The elimination of hormones such as 
thyroid and steroid hormones is one of the common roles of the liver. 
 
2.1.4.7. Phagocytosis Function 
Blood cleansing is also one of the crucial roles played by the liver. Cells of the liver 
phagocytize aged blood cells as well as bacteria leaving the gut and entering the blood. 
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2.1.5 Liver Cirrhosis 
In liver fibrosis, a substantial increase in most matrix proteins are observed especially 
the interstitial collagens type I and III. They are not only present in greater amounts, but 
are deposited in abnormal sites within the liver microanatomy (Dancygier, 2010). Hepatic 
stellate cells found within the space of Disse and the portal fibroblasts embedded in the 
connective tissue are the major cell types associated with the formation of scar tissue as a 
response to liver damage (Antoine et al., 2007). The scar tissue replaces the damaged liver 
cells reducing blood supply and preventing the proper liver function.  
 
2.1.5.1. Role of Stellate Cells and Portal Fibroblasts in Fibrosis of the Liver 
Stellate cells activation is the basic event in liver fibrosis which includes two major 
stages, initiation (pre-inflammatory stage) and perpetuation stage (Friedman, 2002). 
Stellate cells are initially changed by paracrine stimulation derived by all the surrounding 
cells including kupffer cells, hepatocytes, platelets, leukocytes and sinusoidal epithelium. 
Kupffer cells play a major role in the activation process by releasing transforming growth 
factor TGF-α which stimulates stellate cell proliferation (Friedman, 2002) and TGF-β 
which stimulates stellate cell extracellular matrix ECM synthesis (Gressner et al., 2007). In 
addition, kupffer cells secrete matrix metalloproteinase 9 (MMP-9) which activates TGF-β 
that in turn induces the formation of stellate cell collagen (Li et al., 2008). Hepatocytes 
which are the most abundant types of cells in the liver, share in liver fibrosis by releasing 
fibrogenic lipid peroxides. Platelets found in the injured liver are powerful source of 
growth factors (Tsukada et al., 2006) such as platelet growth factor PDGF, TGF-β and 
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epidermal growth factor EGF. During liver injury, leukocytes also play a role in activating 
stellate cells by joining with kupffer cells and produce compounds that change the behavior 
of stellate cells. One of these leukocytes are neutrophils which when activated, act as a 
specific stimulus to stellate cells collagen synthesis by producing reactive oxygen species 
ROS (Tsukada et al., 2006). 
 Perpetuation stage of stellate cell activation includes many changes in the cell 
behavior. Stellate cells start proliferation when induced by PDGF receptors (Iredale, 2007). 
Cytokine chemo-attractors can stimulate stellate cells to migrate towards them (Kumar & 
Sarin, 2007). Stellate cell activation by TGF-β generates hepatic fibrosis through increased 
matrix production.  Lipid peroxidation can stimulate ECM production and the effect of 
these products becomes stronger when there is lack of antioxidants (Brunati et al., 2010).  
 On mechanical stress and repeated injury to hepatic cells or the epithelia of the bile 
duct, the HSCs together with the portal perivenular fibroblasts become active and 
transdifferenciate into myofibroblasts. Microfibroblast acitivation is derived mainly by 
growth factors and fibrogenic cytokines released from Kupffer cells when they are 
activated. The most prominent pro-fibrogenic cytokine is TGF-β (Rockey, 2005; Schuppan 
& Afdhal, 2008). When myofibroblasts are activated, they produce excessive amount of 
collagens, suppress matrix metallproteinases (MMPs) production and overexpression of 
MMPs inhibitors (TIMP-2 and TIMP-1). TIMP-1 can enhance proliferation of 
myofibroblasts and inhibit their apoptosis (Schuppan & Afdhal, 2008). 
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2.1.5.2. The Pathogenic Changes of Fibrosis in Various Liver Diseases 
In liver disease induced by alcohol, alcohol changes the bacteria of the gut resulting in 
an increase in the bacterial flora growth. Lipopolysaccharide increases in portal blood 
activating Kupffer cells to produce reactive oxygen species through NADPH oxidase 
(Bataller & Brenner, 2005). The free radicals especially hydroxyl radical which is the most 
dangerous oxygen radical, may attack and mutate DNA. In addition, free it initiates lipid 
peroxidation, leads to modifications of amino acids and carbohydrates, oxidizes 
nucleobases and reduces the level of antioxidants which eliminate ROS and stimulate the 
activity of cytochrome P450s producing more ROS. Oxidants activate Kupffer cells 
producing more TNF-α which enhances infiltration of neutrophils in addition to the 
production of oxidants by the mitochondria of hepatic cells and induces their apoptosis. 
Acetaldehyde, the main product of alcohol metabolism, activates HSCs and stimulates 
inflammatory and fibrogenic signal (Purohit & Brenner, 2006).  
Hepatitis C virus causes oxidative stress and recruits the inflammatory cells that 
activate HSC and collagen deposition (Kisseleva & Brenner, 2007). In chronic viral 
hepatitis, reactive oxygen species develops pathogenic effects through cell signaling which 
modulate gene expression, cell metabolism and cell death (Choi & Ou, 2006). In addition, 
oxidative stress enhances proliferation of HSCs increasing their production of matrix and 
collagen synthesis (Gressner & Weiskirchen, 2007).   
In chronic cholestatic disorders, cytokines damage bile duct (Bataller & Brenner, 
2005). Biliary cells secrete fibrogenic mediators, which activate portal myofibroblasts as 
well as perisinusoidal HSCs to secrete ECM. Metals such as iron, chromium and copper 
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undergo redox cycling and produce reactive oxygen species. Most enzymes that produce 
ROS contain one of these metals. The presence of such metals in the biological systems in 
their complex form can increase oxidative stress. For example, accumulation of iron in 
tissues causes hemochromatosis, which in turn leads to liver cirrhosis as one of its clinical 
syndromes.  Moreover, Oxidative stress leads to mitochondrial DNA mutations that cause 
abnormal respiratory enzymatic reactions and further oxidative stress (Sligte et al., 2004). 
In Nonalcoholic fatty liver disease (NAFLD) caused by obesity and increase of 
blood sugar level, insulin resistance and hyperglycemia elevates the serum level of fatty 
acids, causing hepatic steatosis.  The receptors which activate proliferation of peroxisome 
and sterol that regulates enzymes responsible for the oxidation and synthesis of fatty acids 
are inhibited causing accumulation of fats in the liver. Hepatocyte necrosis occurs at this 
stage accompanied by hepatocytes death and inflammatory mediators that lead to the 
activation of stellate cells.  
 
2.1.5.3. Symptoms and Complications of Liver Cirrhosis 
In early stages of liver cirrhosis many patients are asymptomatic until the complications 
of the disease appear where approximately 80% - 90% of liver parenchyma is destroyed 
before liver failure is clinically manifested. However when the liver is distorted and loses 
its functions, symptoms become apparent. The symptoms are anorexia, loss of weight, 
itching, feeling fatigue and osteoporosis due to malabsorption of vitamin D and subsequent 
calcium deficiency (Heidelbaugh & Bruderly, 2006). 
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 With the development of the disease, many complications appear. Jaundice is the 
most specific clinical manifestation of liver dysfunction that is characterized by deposition 
of bilirubin causing yellow skin, mucous membranes and sclera. In acute hepatitis and bile 
duct obstruction, bilirubin leaks from the liver to the intestinal tract showing tea-colored 
urine (Dancygier, 2010). Portal hypertension occurs when the portal blood flow is 
obstructed along its course. Sinusoidal hypertension is caused by liver cirrhosis due to 
HSCs, myofibroblasts and vascular smooth-muscle cells contraction when they are 
activated. When portal pressure increases, the metabolic and the synthetic functions of the 
liver are impaired. Bleeding esophageal varices result from the inability of blood to flow 
through the liver resulting in, more blood flowing through the veins of the esophagus and 
causing the veins of the esophagus to balloon outward as a result, they rupture causing 
severe bleeding (Chow & Chow, 2006). Ascites that is accumulation of fluid in the 
peritoneal cavity results from portal hypertension and low serum albumen level (Cárdenas 
& Chopra, 2002). Spontaneous bacterial peritonitis results from intrahepatic obstruction 
of blood and compromised host defenses leading to prolonged bacteremia, gram-negative 
bacteria that infect the ascitic fluid (Dourakis & Sevastianos, 2007). Accumulation of toxic 
substances in the blood stream causes Hepatic encephalopathy as a result of liver failure. 
Toxins such as manganese and ammonia accumulate in the blood and passes to the brain 
causing damage of neurons. In addition, accumulation of ammonia and glutamine may 
contribute to brain edema and can alter the expression of various important brain genes 
(Lemberg & Fernández, 2009). Hepatorenal syndrome constricts the blood vessels of the 
kidneys and dilates blood vessels in the splanchnic circulation, which supplies the 
intestines (Fernández et al., 2007). Kidney function deterioration elevates the creatinine 
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level of the blood, or slows down the clearance of creatinine in the urine (Levey et al., 
2003). Hepatic carcinoma takes place due to mutation of the hepatic cellular machinery by 
many factors as viruses and alcohol (Gurtsevitch, 2008). 
 Cirrhotic cases are usually associated with infertility, so pregnancy is rarely 
considered in liver cirrhosis. Approximately 15-20 % of pregnant women with Chronic 
liver disease suffer spontaneous abortion and Variceal bleeding may also occur during 
labor (Tiribelli & Rigato, 2006). In male patients, gynecomastia and loss of male hair can 
be seen as a result of the formation of oestrone and oestradiol, and the suppression of 
degradation of oestradiol in the liver (Schuppan & Afdhal, 2008). 
 
2.1.5.4. Diagnostic Strategies of Liver Cirrhosis 
Liver function tests are useful in detecting, diagnosing, evaluating severity and 
assessing the prognosis of liver dysfunction. 
a. Serum liver enzymes 
Hepatocyte inflammation causes increase in the enzymes of the liver, alanine 
aminotransferase (ALT), and aspartate aminotransferase (AST). When the liver cell is 
damaged, ALT which is a sensitive marker for liver cell damage, leaks into the blood 
stream showing high ALT blood level. AST is less specific in reflecting liver injury 
because it is also present in other cells of the body. However, the ratio between ALT and 
AST blood levels are useful in assessing the etiology of liver enzyme abnormalities in 
patients (Crosignani et al., 2005). Alkaline phosphatase is (AP) an enzyme found in the 
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cells lining the biliary ducts of the liver, it is also synthesized in bone, intestine and 
kidneys. High levels of AP may indicate bone or liver damage, so it is necessary to confirm 
the source of AP if is of hepatobiliary origin or not by measuring another canalicular 
enzyme such as gamma glutamyl transpeptidase (GGT) which should be normal if the liver 
is not the source of increased ALP (Dancygier, 2010).  
b. Serum bilirubin 
Bilirubin metabolism occurs mainly in the liver. Bilirubin is taken up by liver 
parenchyma, conjugated in the smooth endoplasmic reticulum by being water-soluble 
(direct) and secreted into the bile. In hepatic injury, the liver does not process enough 
bilirubin, so it remains attached to albumin in the plasma as unconjugated bilirubin 
(indirect) (Mukai et al., 2012). Total bilirubin measures the amount of both conjugated and 
unconjugated biliurubin. 
c. Complete blood count 
Thrombocytopenia that is decrease in blood platelets intensifies the damage and 
fibrosis of liver tissues. Thrombocytopenia in Liver Cirrhosis results from the utilization of 
platelets in aggregates with other cells as monocytes. Complete blood count shows the level 
of platelets depending on the severity of the disease (Panasiuk et al., 2007). 
 
d. Prothrombin time 
Measurements of prothrombin time determine the synthetic liver function. It is the 
most prognostic marker in acute liver disease (Giannini et al., 2005). Prolonged 
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prothrombin time reflects deficiency in VII, X, or V prothrombin or fibrinogen, which is 
usually observed in cases of vitamin K deficiency and liver diseases. 
e. Total protein 
Total serum protein test determines the total protein content of the blood including 
albumin and globulin (Higuchi et al., 2003). Low serum albumin indicates liver 
malfunction which usually characterized by ascites. Globulin consists of different proteins 
and some globulins are formed in the liver, while others are produced by the immune 
system. The normal ratio of albumin/globulin is greater than 1 because normally albumin is 
greater than globulin, so less or more ratio than 1 can give clues about problems in the body 
including liver cirrhosis (Wallach, 2006). 
f. Serum cholesterol 
The normal total serum cholesterol depends on normal hepatocellular enzymatic 
activities. In hepatic biliary obstruction, there is a significant rise in the total serum 
cholesterol, while in hepatocellular diseases, the total cholesterol concentration of the 
serum may be normal or slightly reduced (Wallach, 2006). 
g. Liver biopsy 
Liver biopsy is the isolation of tiny samples of liver via percutaneous, transjugular, 
laparoscopic, operation or CT-guided fine-needle or ultrasonography. The tissue is then 
processed, stained and examined under the microscope for histological signs of damage or 
disease (Avunduk, 2008). 
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2.2 Thioacetamide (TAA) 
 
2.2.1. Properties of Thioacetamide 
Thioacetamide (TAA), is an organic compound with the formula CH3CSNH2 (Figure 
2.3). It has other IUPAC names, acetothioamide, ethanethioamide and thioacetamidic acid. 
It is in the form of white crystals under standard conditions, dissolves easily in ethanol and 
water, has melting point between 110 and 115o C. It is stable compound at room 
temperature (Cinghită et al., 2008). 
 In laboratories, TAA serves as a source of sulphur in the synthesis of organic 
compounds such as rubber chemicals, curing agents, cross linking agents, metallurgy, 
pesticides and pharmaceuticals. In addition, it is used as a stabilizer of motor fuels, in 
purification of hydrochloric and sulphuric acids and in leather processing (Cinghită, et al., 
2008). TAA was first used in controlling oranges’ decay and then as a fungicide (Madani et 
al., 2008). TAA is still widely used in qualitative inorganic analysis as a substitute for 
hydrogen sulphide gas (Shen et al., 2012). 
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 Figure 2.3 Structure of TAA (Cinghită, et al., 2008) 
 
 Medically, thioacetamide (CH3-C(S) NH2) is a hepatotoxin and 
hepatocarcinogenic, when administered to experimental animals in their diet inducing 
hepatocellular neoplasms in male rats (Heindryckx et al., 2009). 
 
2.2.2 Mechanism of TAA-Induced Liver Cirrhosis  
Thioacetamide is broadly used by researchers as a chemical model for inducing 
acute and chronic liver damage (Muriel & Rivera‐Espinoza, 2008). Because of its short 
half-life, many researchers used TAA to study mechanisms of hepatic necrosis (Murayama 
et al., 2007), it induces a cirrhotic state in the liver that resembles the case in humans 
(Zimmermann et al., 1987), has wide time range between necrogenesis and liver failure. 
Besides, it has short half-life inside the body (Chilakapati et al., 2005).  
Inside the body, TAA is metabolized to acetate and excreted via urine within 24 hours. 
Short time after TAA administration into the diet of the animal, it is turned into TAA-S-
Oxide (TASO) by microsomal enzymes CYP2E1 of the hepatocytes, and then converted 
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into the toxic metabolite thioacetamide S, S-Dioxide (TASO2) (Figure 2.4). TASO2 is then 
distributed among body organs including plasma, liver, kidney, bone marrow, adrenals and 
other tissues. During biotransformation of TAA, both Cytochrome P450 (CYP) and Flavin-
containing Monooxygenase release superoxide anion, which is changed into the toxic 
Hydrogen peroxide (Sindhu et al., 2006). TAA-induced liver fibrosis is caused by free 
radical-mediated lipid peroxidation. TAA-induced hepatotoxicity occurs due to the binding 
of highly reactive TASO2 covalently to the hepatocyte macromolecules (Sindhu, et al., 
2006) such as lipids, proteins and DNA molecules resulting in hepatocyte necrosis and 
death. Dead hepatocytes release the pro-fibrogenic cytokine TGF-β and also activate 
kuppfer cells which consequently release TGF-β and pro-inflammatory cytokines TNF-α 
and IL-6 (Reeves & Friedman, 2002). These mediators activate HSCs which start 
proliferation expressing ECM especially type-I collagen (Bassiouny et al., 2011). 
Meanwhile, expression of metalloproteinases together with over-expression of their tissue 
inhibitors, increase the deposition of ECM (Park et al., 2010) (Figure 2.5). 
In chronic TAA-induced toxicity, significant liver fibrosis and common regenerative 
developing nodules are accompanied by increase in the pressure of the blood in the portal 
vein and the hyperdynamic circulation attribute of liver cirrhosis (Fan & Weng, 2005). 
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     CH3CSNH2 (TAA)                              CH3CSONH2 (TASO) 
 
                           CH3CSO2NH2 (TASO2) 
 
       Liver Injury                                 Covalent Binding  
 
Figure 2.4: TAA metabolism to TASO2 mediated by CYP2E1 (Chilakapati, et al., 2005) 
 
 
 
 
 
 
 
 
 
 
CYP2E1 
CYP2E1 
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Figure 2.5: Diagram showing the possible mechanism of TAA-induced liver injury. TAA, 
thioacetamide; TASO, thioacetamide sulphur oxide; TASO2, thioacetamide sulphur 
dioxide; TNF-α, tumor necrosis factor α; TGF-β1, transforming growth factor-β1; IL-6, 
interlukin-6; HSCs, hepatic stellate cells; MMPs, matrix metalloproteinases; α-SMA; alpha 
smooth muscle actin; TIMP-1, tissue inhibitor of metalloproteinase-1. 
 
 
2.3. Medicinal Plants 
2.3.1. Antioxidant Properties of Medicinal Plants 
Synthesized antioxidants such as butylate hydroxyl toluene (BHT) and terbutyl 
hydroquinone (TBHQ) have been prevented as food additives due to their toxic effect 
(Damiani et al., 2003). Therefore, the modern strategy is directed towards natural 
(Basyouny et al., 2011) 
(Reeves et al., 2002) 
(Chilakapati, 2005) 
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antioxidants which can be extracted from medicinal plants by the modern techniques of 
fractionation. These natural antioxidants also should be used with great care due to the 
possible adverse affects of some of them such as some flavonoids (Cook & Samman, 
1996). Antioxidants have different compositions; they may be phenolic compounds such as 
flavonoids and flavonones or may be nitrogen containing compounds such as chlorophyll 
derivatives and alkaloids. These compounds play a crucial role in many diseases as cancer 
(Dimitrios, 2006) and liver cirrhosis such as Silymarin which is a very well recorded 
antioxidant extracted from the seeds of Silybum marinum and it was reported as a highly 
hepatoprotectant (Girish & Pradhan, 2008). 
 
Figure 2.6: The structure of Silymarin (Singh, 2004) 
 
Many studies have been conducted on Silymarin and reported that it is highly anti-
inflammatory antioxidant (Ramasamy & Agarwal, 2008) enhancing the activity of RNA 
polymerase I that plays a role in blocking the uptake of toxins (Yadav et al., 2008). 
Furthermore, Silymarin has high scavenging capacity to free radicals and strongly inhibit 
lipid peroxidation (Fraschini et al., 2002). 
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2.3.2. Medicinal Plants and Liver Diseases 
Recently, many compounds have been isolated from different medicinal plants and 
reported to have hepatoprotective activities. The herbal mixture 861 contains mixed chinese 
herbs and was proved to regulate mRNA expression of α-SMA in HSCs In vitro (Wang et 
al., 2008). Rosmarinic acid was proved to enhance apoptosis of HSCs (Zhang et al., 2011).  
Silymarin is a natural product that contains three polyphenol compounds, silybinin, 
silychristin and silydianin was reported to have high antioxidant power and inhibit HSC 
activation into myofibroblast (Pradhan & Girish, 2006). Curcumin is a natural product 
isolated from C. longa rhizomes and was shown to have anti-inflammatory properties and 
inhibit NF-kB (Bruck et al., 2007).  
 
2.4 Zingiberaceae Family 
2.4.1 Morphology and Distribution 
Family Zingiberaceae is one of the largest families from the order Zingiberales. 
Zingiberaceae species grow naturally scattered in moist, shaded parts of lowland areas and 
slopes of hills, where the leaves and fleshy rhizomes of most members of the family have 
aromatic characters when they are both crushed. Several studies showed that the members 
of the zingiberacae family consist of different active phytochemicals in addition to 
antioxidative, anti-inflammatory, anticancer and anti-tumour promoting activity (Basak et 
al., 2010).  
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2.4.2. Boesenbergia rotunda (L.) 
 
Figure 2.7: Boesenbergia rotunda rhizomes (http://www.indonesian-culinary.com 2010) 
Table 2.1: Taxonomy of Boesenbergia rotunda (L.) 
Kingdom Plantae 
Subkingdom Trachiobionta 
Division Magnoliophyta 
Class Liliopsida 
Order Zingiberales 
Family Zingiberaceae 
Genus Boesenbergia 
Species rotunda 
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One of the species of family Zingiberaceae is Boesenbergia rotunda (L.), (Figure 
2.7), (Table 2.1), which is a perennial herb locally known as “Kra-chai” in Thai, “temu 
kunchi” in Malaysia, Chinese ginger in China and in English, it is traditionally called 
Fingerroot because of its finger-like rhizomes. It is used commonly in Southeast Asia as 
folk medicine for treating several diseases such as, stomach discomfort, dysentery and 
leucorrhea. Moreover, the fresh rhizomes of Boesenbergia rotunda is commonly used by 
natives of Southeast Asia in cooking and its tonics are added to lotions to treat rheumatism 
and muscle pain (Ching et al., 2007). 
In Malaysia, Fingerroot plant is popularly known as cekur which is used by almost 
all households in the Malay custom as culinary plant as well as medication purposes. 
Drinking the water in which the fresh edible roots are boiled, has a good effect in 
rejuvenating women after giving birth and the regular drinking of this water can also be 
anti-aging. It is believed that chewing the bulbous roots helps to treat sore throat. Malay 
can identify the types of cekur species by a simple practice, rubbing the bulbous roots 
against the core of banana tree, turning reddish indicates the right species that has good 
medical properties. 
Hexane and chloroform extracts of rhizomes of Boesenbergia rotunda (L.) 
separated three flavanones, pinostrobin, alpinetin and pinocembrin, and the chalcones, 
boesenbergin A and cardamonin (Ching et al., 2007). The ethanolic extract of leaves, stems 
and rhizomes of B. rotunda showed high contents of Kaempferol and Quercetin (Figure 
2.8), (Yob et al., 2011). 
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 Quercetin (3,3',4'5,7-pentahydroxy flavone) 
 
 
Kaempferol (3,4',5,7-tetrahydroxyflavone) 
Figure 2.8: Chemical structures of Quercetin and Kaempferol (Škerget et al., 2005) 
 
Panduratin A is cyclohexenyl chalcone from Boesenbergia rotunda rhizomes 
exhibited many activities in vitro and in vivo studies such as anticancer (Cheah et al., 
2011), proapoptosis, antiproliferative, anti-inflammatory, and antioxidant. It has been 
reported to stimulate anti-inflammatory activity in animals experiment. The bactericidal 
activity of Panduratin A against biofilm organisms has been reported (Rukayadi et al., 
2009). It showed suppressive activity to COX-2 in laboratory animal peritoneal 
macrophages (Yun et al., 2006). Cheah, et al, (2011) reported that Panduratin A inhibited 
NF-kB in A549 cells. In addition, Panduratin A provides the protected hepatoma cells 
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against t-BHP-induced damage (Sohn et al., 2005). Furthermore, recent studies showed that 
Panduratin A has Antiangiogenic activity in vivo and in vitro (Orlikova et al., 2011) 
 
2.4.3 Curcuma longa (L.) 
 
Figure 2.9: Curcuma longa rhizomes (http://www.ramuantaufiq.com 2011) 
Table 2.2: Taxonomy of Curcuma longa  
Kingdom Plantae 
Subkingdom Trachiobionta 
Division Magnoliophyta 
Class Liliopsida 
Order Zingiberales 
Family Zingiberaceae 
Genus Curcuma 
Species longa 
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Curcuma longa is another rhizomatous perennial plant species (Figure 2.9) that belongs to 
the family Zingiberaceae (Table 2.2), originally found in South Asia and commonly known 
as turmeric, indian saffron and curcumin (Bhowmik et al., 2009). Recently, studies suggest 
that it reduces the symptoms of irritable bowel syndrome, ulcerative colitis, and 
osteoarthritis (Fischer & Mullin, 2012). In Okinawa and Japan, turmeric is used as a Tea, in 
Pakistan, as a medicine for treating digestive disorders and anti-inflammatory, in 
Afghanistan and Northwest Pakistan, applied to wounds for cleansing and fast recovery, 
and in India used in skin creams. Currently, 19 clinical trials have been registered by the 
U.S. National Institutes to study the effect of turmeric on many clinical disorders (Shehzad 
et al., 2010). 
 In Malaysia, kunyit is the popular name of Turmeric plant and considered as a 
common plant for culinary dishes. In addition, it is used as a herbal medicine because 
people believe in its different medicinal properties. The concoction from boiling turmeric is 
used to treat irritation in the eyes. Concentrated turmeric oil is used to treat arthritis. The 
liquid obtained from scraped and pressed turmeric is mixed with egg yolk to treat gastric 
disorders. Moreover, a published Malaysian article had described the effective use of 
Kunyit in strengthening gall bladder, degrading blood clot and reducing toxin in liver 
(Bruck et al., 2007). 
 High Performance Liquid Chromatography of Curcuma longa showed that it 
contains Curcumin, demethoxycurcumin, bisdemethoxycurcumin, ar-turmerone and 
curlone. Curcumin which is the coloring substance in Curcuma longa together with 
demethoxycurcumin, bisdemethoxycurcumin are known as curcuminoids (Dandekar & 
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Gaikar, 2003), (Figure 2.10). Curcuminoids together with sesquiterpenoids were found to 
decrease blood glucose level in diabetic mice (Nishiyama et al., 2005). Curcuminoids also 
have anticancer activity (Jankun et al., 2006) and are inhibitors of HIV-2 and HIV-1 
proteases (Itokawa et al., 2008). In addition, the oil isolated from of C. longa was found to 
contain many components, ar-turmerone (51.8%), ar-turmerol (11.9%). These studies 
indicated that C. longa is an effective antifungal material (Singh et al., 2002). 
 
 
Figure 2.10 Chemical structures of Curcuminoids (Dandekar & Gaikar, 2003) 
. 
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Germacrone, is a sesquiterpene component of C. longa rhizomes (Jayaprakasha et al., 
2005). After 2006, it was found that it significantly enhances the release of cytochrome C 
and Bok expression out of mitochondria (Liu et al., 2012). Researchers reported, 
germacrone might protect animals against inducers such as D-galactosamine and lipo 
polysaccharide in liver injury in mice (Yoshikawa et al., 2006). It was suggested that 
germacrone might be a new potent chemopreventive drug candidate for liver cancer by 
regulating protein expression related to the cycle of cell and apoptosis which may be 
important in the inhibition of human liver cancer cells (Liu et al., 2012). 
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CHAPTER III 
METHODOLOGY 
3.1. Plant Preparation and Extraction 
Plant extraction using solvents with different polar properties have been used in 
research. Researchers suggested that ethanol is capable of yielding high quantity of the 
crude extract compared to aqueous extraction due to its polar solvent property, high 
volatility and higher penetration susceptibility (Pinelo et al., 2005). Moreover, the type of 
the solvent used affects the concentration of the antioxidant compound constituents of the 
crude extract (Turkmen et al., 2006) Therefore, ethanol was selected for plant extraction in 
the present study. Fresh rhizomes of the plants Boesenbergia rotunda and Curcuma longa 
were purchased from a commercial company (Ethno Resources Sdn Bhd, Selangor 
Malaysia), and identified by comparing them with the voucher specimen deposited at the 
Herbarium of Rimba Ilmu, Institute of Science Biology, University of Malaya, Kuala 
Lumpur. After initial washing with tap water followed by distilled water, the rhizomes 
were sliced and left in the shade for a duration of 10 days to dry. The dried samples were 
then grounded finely and 100 g of the resulting powder was mixed in 1000 mL 95 % 
ethanol for 7 days at room temperature. The ethanol extract was distilled under a reduced 
pressure in Rotary Evaporator (Rotavapor, Buchi R-215, Switzerland), and dried at 40oC in an 
incubator for 3 days giving a gummy yield of 9.49 % (w/w) for B. rotunda and dark yellow 
gummy yield (7%, w/w) for C. longa. 
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3.2. Evaluation of the Antioxidant Capacity of the Crude Extracts 
3.2.1. The Activity of Scavenging DPPH 
The scavenging activity of the B. rotunda and C. longa crude extracts was 
determined using 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) stable free radical 
scavenging assay. The purple hue which is usual for free DPPH radical decays and the 
decrease in the reading of the spectrophotometer at 517 nm can be recorded. This assay 
evaluates the free radical scavenging capability of the crude extract. The assay was 
conveyed out according to the procedure explained by (Gorinstein et al., 2003) with little 
modification. In brief, 1 ml of dimethyl sulfoxide was used to dissolve 1 mg from each 
ethanolic extract and then diluted to the concentrations (50, 25, 12.5, 6.25 and 3.125 
μg/mL), Ascorbic acid and Trolox were utilized as antioxidant standards. An amount of 
195 μL of 100 μM DPPH was added to 5 μL from each plant extract and the standards in 
triplicate. The resulting decrease in the spectrophotometer reading was assessed at 517 nm 
by UV 1601 spectrophotometer for two hours with twenty minutes gaps. The power of 
scavenging DPPH radical was determined from the following formula and the analysis of 
the results was recorded as Mean ± SEM:  
% of fundamental scavenging activity = (Abs blank – Abs sample) /Abs blank X100 
 
3.2.2. Ferric Reducing Antioxidant Capacity (FRAP) 
The anti-oxidant power of B. rotunda and C. longa crude extracts was also 
determined using a test sensitive to its scavenging ability towards reactive oxygen species 
or reagents containing iron. In this regard, the ferric reducing anti-oxidant power (FRAP) 
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of both plant extracts was determined using an assay by following the method described in 
(Benzie & Strain, 1996), with a slight modification.  The FRAP reagent was prepared by 
mixing 300 mM acetate buffer (3.1 mg sodium acetate/ml, pH 3.6), 10 mM 2,4,6-
tripyridyl-S-triazine (TPTZ) (Merck, Darmstadt-Germany) solution and 20 mM FeCl3.H2O 
(5.4 mg/mL). The B. rotunda and C. longa crude extracts, and the standards Ascorbic acid 
were sampled in amounts of 10 µL of 1mg/mL along with 10 µL of 0.1mg/mL silymarin 
and added into 300 µL of the reagent TPTZ separately in triplicate. The absorbancies of the 
resulting mixtures were read using ELISA reader (UV 1601 spectrophotometer, Shimadzu, 
Kyoto, Japan) at 593 nm wavelength at 0 minute and after 4 minutes. We note that the 
dynamic range of the instrument was limited to read the dose amounts of 500 mg/kg for the 
B. rotunda and C. longa crude extracts and 50 mg/kg dose for silymarin administered to the 
rats daily, as described below. To compensate this deficiency, we performed the 
measurements in equivalent amounts obtained by scaling the administered doses up by 20 
times, respectively. The purpose of adding Silymarin was to compare the iron chelating 
power of the plant extracts to Silymarin as a hepatoprotectant compound recently proved 
for this property (Moayedi et al., 2013) The readings from both plant extracts and silymarin 
were compared against the standards Ascorbic acid and Trolox (Asghar & Masood, 2008).  
 
3.2.3. Total Phenolic Content (TPC) Evaluation 
The colorimetric method of Folin Denis using the reagent Folin-Ciocalteau (Merck, 
Darmstadt, Germany) was performed to measure the total phenolic content of the B. 
rotunda and C. longa crude extracts and the result was expressed equivalent to gallic acid 
(μg GAE/mg extract) (Cunniff, 1995). An amount of I mL DMSO was used to dissole 1 mg 
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of each crude extract or 0.1 mg of Silymarin was. Next, 20 µL of the extract or Silymarin 
was added to 100 µL of Folin-Ciocalteau reagent, followed by 3 minutes incubation of the 
mixture in the dark. Then, the resulting mixture was mixed with 100 µL of  Na2CO3 
solution (1g/10 mL). The final mixture was re-incubated in the dark for 1 h and the 
spectrophotometer was read at 750 nm wavelength. All procedures were carried out in 
triplicate. Serial dilution of gallic acid (1 mg/mL DMSO) was used to produce linear 
standard curve and the absorbance was read at 750 nm. 
 
3.3. Animal Experiments 
3.3.1. Animals 
One hundred and two wholesome rats of the species Sprague Dawley (180-250 g) 
were used in the experiments on the crude extracts. All the experimental rats were placed in 
special cages at 25 ± 2°C, given pellet and water and the 12-h light/dark circuits was 
adjusted to be in a special room prepared for animals at 50–60% humidity.  Throughout all 
the experiments, all animals obtained human care according to the criteria delineated in the 
“Guide for the Care and Use of lab Animals” prepared by the National Academy of 
Sciences and released by the National institute of Health. Animal protocols governing all 
experiments were approved by the Ethics Committee for Animal Experimentation, Faculty 
of Medicine, University of Malaya, Malaysia PM/07/05/2008/MMA (a) (R) (Appendix I). 
 
40 
 
3.3.2. Acute Toxicity Study of Crude Extracts 
The toxicity of the B. rotunda and C. longa crude extracts was evaluated in 60 
normal healthy Sprague Dawley rats by subjecting them significantly to low and high doses 
of the extract. Rats were assigned equally into 5 groups, each with 6 males and 6 females, 
labelled as vehicle (5 mL/kg, 10% Tween-20), and 2 g/kg and 5 g/kg for each rhizome 
extract preparation, respectively (Table 3.1). The rats were deprived of food but not water 
prior to the dosing. Food was withheld for another 3-4 hours after the dosing. The animals 
were observed at 30 min and 2, 4, 8, 24 and 48 hours after the oral administration to detect 
the onset of clinical or toxicological symptoms. The animals were sacrificed on day 15. 
Through the jugular vein, blood was collected directly at the time of the sacrifice. 
Histological and serum biochemical parameters (liver enzymes, lipid profile, plasma 
protein and Prothrombin time) were determined following the standard methods (Mahmood 
et al., 2010). 
 
Table 3.1 Experimental design of the acute toxicity test of B. rotunda and C. longa crude 
extracts  
Species Sprague Dawley rats 
Age 6 – 8 weeks 
Number of animals 6 of each sex per dose level, for each rhizome extract 
Dosage 
Low dose groups 
2g/kg B. rotunda 
2 g/kg C. longa 
High dose groups 
5g/kg B. rotunda  
5g/kg C. longa 
Vehicle group 
10% Tween 20 
Observation period 14 days 
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3.3.3. In vivo Hepatoprotective Activity of the Crude Extracts and Silymarin against TAA 
Toxicity 
A set of experiments were carried out to test the therapeutic effects of the B. 
rotunda and C. longa crude extracts on liver cirrhosis. For this purpose, 42 male Sprague 
Dawley rats were randomly divided into 7 groups of 6 rats each. The plant extracts and the 
Silymarin that is used as a standard drug (International Laboratory, USA) were prepared by 
completely dissolving in 10% Tween 20 and sterile distilled water to be orally administered 
to animals (5 mL/ kg body weight). The oral acute toxicity test of the ethanol extract of B. 
rotunda and C. longa showed no mortality at the highest dose 5 g/kg. Therefore, 5 g/kg was 
considered LD50 cut off dose and 1/10 and 1/20 of LD50 were selected (500 mg/kg and 250 
mg/kg) for the experiment.  The preparation of TAA was done by complete dissolving of 
its crystals (Sigma-Aldrich, St Louis, MO, USA) in sterile distilled water (Aydın et al., 
2010). Group 1 rats (normal control group) were given oral administration of 10% Tween-
20 (5 mL/kg) daily and intraperitoneal injection of sterile distilled water (1 mL/kg) thrice 
weekly. To induce liver cirrhosis, groups 2–7 were intraperitoneally injected by TAA (200 
mg/kg) three times a week. The pathological changes induced by constant exposure of this 
concentration of TAA were reported to be comparable to the etiology of cirrhosis in 
humans (Beale et al., 2008). Group 2 rats (group of cirrhosis control) were by mouth 
administered 5 ml/kg 10% Tween-20 daily. Rats of Group 3 (group treated with Silymarin) 
were by mouth administered a daily dose (50 mg/kg) of Silymarin. Rats of Groups 4 and 5 
were by mouth administered B. rotunda extract at daily doses of 250 mg/kg and 500 mg/kg, 
respectively. Rats of Groups 6 and 7 were by mouth administered C. longa extract at daily 
doses of 250 mg/kg and 500 mg/kg, respectively. This treatment protocol for rats over an 8 
week period with Silymarin or B. rotunda extract or C. longa extract in parallel; slows 
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down progression of liver fibrosis and protects the liver from further damage and therefore 
is considered preventive. At the end of the 8-weeks period of the experiment and after the 
last treatment, the rats were allowed to fast for 24 hours and sacrificed under ketamine (30 
mg/kg, 100 mg/mL) and xylazil (3 mg/kg, 100 mg/mL) anesthesia (Fatemi et al., 2010). 
The blood of the jugular vein from all animals was collected for biochemical tests, 
prothrombin time, cytokines and apoptotic proteins assessment. Ice cold normal saline was 
used to wash liver tissues after being excised. Following blotting on filter paper, liver 
tissues were then weighed, examined for gross pathology and eventually collected for the 
assessment of cellular damage and histopathology.  
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Table 3.2: Experimental design of the hepatoprotective effect of B. rotunda and C. longa 
crude extracts  
Group 
Number 
of 
animals 
Intraperitoneal 
injection (three 
times/week) 
Oral administration 
(5mL/kg) 
Durations 
(weeks) 
Normal 
control 6 
Sterile Distilled 
Water (1mL/kg) 10% Tween 20 8 
Cirrhosis 
control 6 TAA 10% Tween 20 8 
Reference 
control 6 TAA Silymarin 50mg/kg 8 
Low dose  
B. rotunda 6 TAA B. rotunda 250mg/Kg 8 
High dose 
 B. rotunda 6 TAA B. rotunda 500mg/kg 8 
Low dose 
 C. longa 6 TAA C. longa 250mg/kg 8 
High dose  
C. longa 6 TAA C. longa 500mg/kg 8 
 
3.3.3.1. Postmortem Liver Tissue Analysis 
For histopathological analysis, the liver specimens were fixed in 10 % buffered 
formaldehyde, processed by automated tissue processing machine (Leica, Germany) and 
then embedded in paraffin wax. Sections were prepared in 5 μm-thicknesses, stained with 
hematoxylin-eosin (H&E) (Budak et al., 2011) and examined under the light microscope. 
For determining the normality of hepotocytes, the number of normal cells were counted at 
the center of the cirrhotic area as well as the normal areas adjacent to both sides of the 
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cirrhotic area using a light microscope with an oil immersion objective (x40) covering 0.15 
mm2 (Al Bayaty et al., 2010). Dead hepatocytes could be differentiated by having no or 
small dark-stained or big dark-stained nucleus, while normal hepatocytes acquired big 
light-stained nucleus with clear chromatin. Percentage of the normal cells was calculated 
by using the formula: 
% Normal cells = [(Normal cells/ (Normal + dead cells) x 100]. 
 
3.3.3.2. Histopathological Analysis 
Five µm-thick sections of liver samples were prepared and divided into two groups 
of slides. One group of slides was stained with hematoxylin and eosin (H&E, Appendix II, 
P. 182) for routine examination of the liver tissue histopathology and architecture. The 
second group of slides was stained with Masson’s Trichrome (Sigma, USA, Appendix II, P. 
184) as a marker for detecting the degree of fibrosis (Zeisberg et al., 2007) and identifying 
collagen fibers in liver tissues (Edgtton et al., 2004). The tissue slides were examined under 
light microscope and Nikon microscope (Y-THS, Japan) was used to capture digital images 
(magnification ×20). 
 
3.3.3.3. Biochemical Analysis 
For the assessment of specific liver markers, blood samples were collected from all 
rats into carefully labelled gel-activated tubes. Sodium citrate tubes were used to collect 
another group of blood samples to determine prothrombin time. After leaving the blood to 
clot, the gel-activated tubes were transferred to the centrifuge which was adjusted at 3400 
45 
 
rpm for 10 min at 4°C. The resulting samples of serum were collected and divided into 
aliquots and then kept at -80oC. For measuring the liver markers, alkaline phosphatase 
(AP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-
glutamyl tranferase (GGT) lactate dehydrogenase (LDH), total protein, albumen and 
bilirubin and lipid profile, aliquots were sent to the Medical Center of University of 
Malaya where the samples were spectrophotometrically assayed by standard automated 
techniques of the Central Diagnostic Laboratory (CDL). 
 
3.3.3.4. Protein Content Assay 
Liver tissues from all experimental animals were collected and washed in ice-cold 
PBS (0.02 mol/L, pH 7.0-7.2) to remove excess blood. One gram of each liver was 
sampled, mixed with 10 mL PBS (pH 7.2) and then homogenized using HG 15A 
homgenizer (DAIHAN Sci., Seoul, Korea). The resulting tissue homogenate was 
centrifuged at 5000 xg for 5 minutes using Rotofix 32 centrifuge (Hettich Zentrifugen, 
Germany). The supernatant was collected and divided into aliquots and then kept at -80oC 
till being assayed. The protein content in the liver tissue homogenate collected from all 
animals was assayed by using bovine serum albumin (BSA) according to (Lowry et al., 
1951) with slight modification. In brief, 10 serial dilutions of BSA were prepared to the 
final concentration 100 mg/L. 700 μL of Lowry solution was added to 500 μL of each 
sample or standard. All samples were designed in triplicate and incubated at room 
temperature in the dark. After 20 minutes of incubation, 100 μL of diluted 2N Folin-
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Ciocalteau's Phenol Reagent (1:1) was added and incubated for 35 minutes followed by 
reading the optical density at 750 nm. 
3.3.3.5. Assessment of Hepatic CYP2E1 Levels 
To demonstrate the effect of the crude extracts of B. rotunda and C. longa rhizomes 
on the level of CYP2E1 as an important enzyme in the biotransformation of TAA in the 
liver microsome (Amali et al., 2006), the tissue homogenate from all rats was tested for 
the level of CYP2E1 enzyme by following the instructions of Uscn Life Science sandwich 
enzyme immunoassay (E90988Ra, China, Appendix II p. 185).  Briefly, 100 µL of the 
sample was incubated with pre-coated capture antibody specific to CYP2E1 in duplicate in 
96-well plate for 2 hours at 37oC. After brief rinsing, the sample was incubated for 1 hour 
at 37oC with 100 µL of biotin-conjugated secondary antibody followed by three times 
washing using 350 µL washing buffer (1x). 100 µL Streptavidin-Horse radish peroxidase 
(HRP) was added to the sample and incubated for 30 minutes at 37oC followed by 5 
repeated washes. 90 μL Tetramethylbenzidine (TMB) was added to the sample as a 
colorimetric reagent and incubated for 20 minutes. Finally, the reaction was stopped using 
50 µL of H2SO4 and the absorbance was read at 450 nm.  
 
3.3.3.6. Evaluation of Oxidative Stress Markers 
              (a) Urine 8 Hydroxy Deoxyguanosine (8-OH-dG) 
Oxidative damage of DNA due to free radicals-induced oxidative stress, produces 
(8-OH-dG) (Valavanidis et al., 2009) and therefore it serves as an established oxidative 
stress marker (Beckman & Ames, 1997). For this purpose, clean urine samples from all 
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animals were collected 24 h before sacrifice by tickling the back of the animal gently while 
holding its tail and collecting the urine in 5 mL clean polystyrene disposable beakers after 
cleaning the periurethral area of the animal (Kurien et al., 2004). Collected urine samples 
were kept at –80°C before assaying for OH-dG levels following the instructions of the 
manuals (Genox KOG-HS10E, USA, Appendix II, p. 190). Briefly, in triplicate in a 96-
well microtiter plate, pre-coated with monoclonal antibody specific for 8-OH-dG, 50 µL of 
clear urine sample was incubated at 4oC overnight. The plate was then washed 5 times with 
concentrated buffered saline (pH=7.4). 100 µL of biotinylated secondary antibody was 
added to the sample and incubated for one hour at room temperature followed by 3 times 
washes. 100 µL of the chromatic solution tetramethylbenzidine (TMB) was added and 
incubated at room temperature for 15 minutes in the dark. 100 µL of the reaction 
terminating solution (1M phosphoric acid) was added and the plate was read at 450 nm.  
 
               (b) Hepatic Nitrotyrosine 
Nitrotyrosine, as a marker of protein oxidation (Bruck, et al., 2007) was assessed in 
the liver of animals by ELISA immunoassay guided by the manufacturer’s instructions 
(MyBiosource MBS722419, USA, Appendix II, p. 193). Succinctly, 100 µL of the sample 
was incubated with monoclonal Nitrotyrosine-HRP conjugate in duplicate in a microtiter 
plate. After one hour of incubation, the plate was washed 5 times using 350 µL wash 
solution (x1). 100 µL of substrate specific to HRP enzyme was added to the sample 
followed by 50 µL stop solution and the intensity of the produced colour was measured 
spectrophotometrically at 450 nm.  
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               (c) Hepatic Malondialdehyde (MDA) 
Malondialdehyde levels were measured in the liver tissue homogenate of all 
experimental groups as a measure for lipid peroxidation (Del Rio et al., 2005) using 
thiobarbituric acid according to the manufacturer’s instructions (Cayman Cat. # 10009055, 
Appendix II, p. 199). To 100 µL sample or standard, 100 µl of the provided SDS solution 
was added followed by the addition of 4 mL of the colour reagent. Samples and standard 
solutions vials were kept in boiling water for 1 hour and the reaction was stopped by 
immediate incubation in ice bath for 10 minutes. All vials were then centrifuged at 1600 xg 
for 10 minutes at 4oC and 150 µL of each sample or standard was loaded onto 96-well plate 
in duplicate, and then the absorbance was read at 532 nm. 
 
3.3.3.7. Antioxidant Enzyme Assessment 
Superoxide dismutase (SOD) catalase (CAT) and glutathione peroxidase (GPx) 
enzymes were determined in the liver homogenates collected from all animal groups using 
Cayman kits according to the manual’s instructions (Cayman Cat. # 706002, # 707002 and 
# 703102 respectively, Appendix II, PP. 205, 212 and 219). SOD activity was evaluated by 
tetrazolium salt detecting superoxide radicals produced by the action of xanthine oxidase 
on hypxanthine. Bovine erythrocyte SOD was used to represent SOD standard curve. 
Tetrazolium salt solution (200 µL) was added to 10 µL standard or sample followed by fast 
addition of 20 µL of 8 xanthine oxidase to initiate the reaction. The plate was covered and 
incubated for 20 minutes on a plate shaker (Barnstead Dubuque, USA) and the reading of 
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the spectrophotometer was recorded at 450 nm. CAT activity was evaluated by the 
chromagen, 4-amino-3 hydrazino-5-mercapto-1,2,4-triazole which measures the 
formaldehyde produced by the reaction of CAT enzyme with methanol in the presence of 
H2O2. The standard curve was obtained by catalase formaldehyde standard. 100 µL of 
assay buffer and 30 µL of methanol were added to 20 µL of standards/samples and the 
reaction was initiated by fast addition of 20 µL of H2O2. The plate was incubated in the 
dark at room temperature for 20 minutes, followed by the addition of 30 µL of potassium 
phosphate buffer to terminate the reaction. An amount of 30 µL of the chromagen was 
added and the plate incubated on the shaker at room temperature in the dark. After 10 
minutes of incubation, 10 µL of catalase potassium periodate was added and the plate 
covered and then left for five minutes on the shaker at room temperature before recording 
the reading of the spectrophotometer at 540 nm. The principle of GPx assay depends on the 
indirect measure of GPx activity by a coupled reaction. GPx reduces hydroperoxide into the 
oxidized form glutathione (GSSG) which is recycled by NADPH into its reduced form 
glutathione reductase (GR). All assays where performed in triplicate.  
 
3.3.3.8. Assessment of Cytokines  
Sera aliquots collected from all rats were assayed for transforming growth factor-
beta (TGF-β1) as a fibrogenesis-driving cytokine (Gressner et al., 2007) by ELISA as per 
the manufacturers’ instructions (Abnova, KA0416, USA, Appendix II, P. 225). Briefly, the 
capture antibody was diluted with the sample buffer provided and added onto 96-plate pre-
coated with anti-rat antibody specific to TGF-β After the recommended incubation period, 
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biotinylated anti-rat specific antibody was added and left incubated at 37oC in the dark. 
Following 3 washes with the provided wash buffer, the samples and the standards were 
incubated in with streptavidin-HRP conjugate which was finally removed by 5 washes with 
the wash buffer. The wells were then incubated with the colorimetric reagent TMB and the 
reaction was stopped so that to read the absorbance at 450 nm. The concentrations were 
calculated by the optical density measurements from the obtained standard curve. The 
nuclear transcription factor NF-ĸB and the pro-inflammatory cytokine interlukin IL-6 as 
important signals in liver injury (Mandrekar & Szabo, 2009) were assayed in the sera 
aliquots by enzyme-linked immunosorbent assay in duplicate following the instructions of 
the manufacturer (Uscn Life Science, China E91824Ra, for NF-ĸB and E90079Ra for IL-6, 
Appendix II, P. 230 and 235). 
 
3.3.3.9. Pro-apoptotic Bax, Anti-apoptotic Bcl-2 and caspase-3 Assessment 
Based on many studies, it was found that the triad Bax, Bcl-2 and caspase-3 are 
involved in the apoptosis of hepatocytes during liver injury (Elsharkawy et al., 2005) To 
demonstrate the effect of B. rotunda and C. longa rhizome extracts on the apoptosis of liver 
cells, rat Bax ELISA kit (Uscn Life Science E91824Ra, China), rat Bcl-2 ELISA kit (Uscn 
Life Science E90778Ra, China), and rat caspase-3 ELISA kit (Uscn Life Science 
E90626Ra, China) (Appendix II, PP. 238, 241 and 244) were used to evaluate the 
expression of Bax, Bcl-2 and caspase-3 in the sera aliquots collected from all rats. Prior to 
use, sera samples stored at -80oC were warmed up in 37oC bath and then assayed in 
duplicate according to the instructions supplied by the company. The absorbance was read 
at 450 nm and the concentration ratio of Bax/Bcl-2 was calculated.  
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 3.3.3.10. Evaluation of Matrix Metalloproteinase enzymes (MMP-2 and MMP-9) and TIMP-1 
Matrix metalloproteinase enzymes (MMP-2 and MMP-9) and their partial regulator 
tissue inhibitor of metalloproteinase (TIMP-1) play a role in liver damage (Okazaki et al., 
2003). For this purpose, the following assay was conducted to perform the effect of B. 
rotunda and C. longa rhizome extracts on these enzymes in the liver tissue homogenate 
collected from the rats of all groups as mentioned previously and assayed in duplicate by 
enzyme-linked immunosorbent assay kit following the kits’ manuals (Uscn Life Science 
E90100Ra, E90553Ra and E90552Ra, China, Appendix II, PP. 247, 250 and 253). 
 
3.3.3.11. Immunohistochemistry  
 Using poly-L-lysine-coated slides, liver sections were prepared and heated in an oven 
(Venticell, MMM, Einrichtungen, Germany) for 25 minutes at 60oC. After heating, xylene 
was used to deparaffinize and graded alcohol to rehydrate liver sections. Sodium citrate 
buffer was used for antigen retrieval. The steps of immunohistochemistry staining were 
performed following the manual’s instructions (DakoCytomation, USA, Appendix II, P. 
256). In brief, 0.03% hydrogen peroxide sodium azide was used to block the endogenous 
peroxidase for 5 min followed by washing the tissue sections gently with wash buffer and 
then incubated with Bcl-2–associated X protein (Bax) (1:500), Proliferating Cell Nuclear 
Antigen (PCNA) (1:200) and anti-apoptotic protein Bcl2 (1:50) (Santa Cruz Biotechnology 
Inc, California, USA) biotinylated primary antibodies for 15 minutes. After incubation, 
sections were re-washed gently using wash buffer and kept in the buffer bath in a humid 
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chamber. Sections were then incubated for 15 min with Streptavidin-HRP followed by 
washing. Further, sections were incubated with diaminobenzidine-substrate chromagen for 
over 7 min followed by washing and hematoxylin counterstaining for a period of 5 seconds. 
A solution of weak ammonia (0.037 mol/L) was used in dipping the sections 10 times. The 
sections were then washed and cover slipped. Light microscopy was used to examine the 
brown-stained positive antigens. Light microscopy was used to examine the brown-stained 
positive antigens.  
 
3.3.4. Isolation of Compounds from their Crude Extracts 
3.3.4.1. Instrumentation 
(a) Column Chromatography  
Agilent XDB C-18 Reversed phased column, dimensions 4.6 x 250 mm and Particle size, 
5.0 μm. 
(b) HPLC Components 
Agilent 1100 Series Diode Array and Multiple Wavelength Detectors 
HPLC parameters 
Volume of injection: 100 µL 
Solvents: A: Acetonitrile , B: Milli-Q Water (Millipore, USA) (0.25% acetic acid) 
Flow rate: 1.2 mL/ min 
Post run: 2 minutes 
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Table 3.3: HPLC gradient conditions 
 
Time A% B% 
0 45 55 
10 45 55 
15 60 40 
20 60 40 
25 80 20 
30 45 55 
32 45 55 
 
(c) LCMS components 
Instrument: Agilent 1200 Series HPLC system with Capillary pump and degasser, micro-
well plate sampler with thermostat, and Agilent 6520 Accurate-Mass Q-TOF mass 
spectrometer with dual ESI source. 
LC Parameters: 
Column Used: UHC small molecule chip with 500 nL enrichment column and 75 µm x 
150 mm separation column packed with Zorbax 80SB-C-18 5µm material. 
Solvents for capillary pump: (A) 0.1% formic acid in water (B) 90% acetonitrile in water 
with 0.1% formic acid. 
Solvents for Nano pump: (A) 0.1% formic acid in water (B) 100% acetonitrile in water 
with 0.1% formic acid. 
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Injection Volume: 1µL. 
Flow Rate: Capillary pump 4 µL/min and Nano pump 0.4 µL/min. 
Table 3.4: LC gradient conditions 
Time (min) A% 
Initial 95 
10 95 
17 95 
17.1 40 
 
Sample Analysis: Isocratic run with Acetonitrile + 0.1% Formic acid for 30 minutes 
MS Parameters: 
Ion Polarity: Positive & Negative 
Vcap: 3500V 
Fragmentor Voltage: 125V 
Skimmer: 65 V 
OCT 1 RF Vpp: 750 V 
Drying Gas: 5L/ min 
Gas Temperature: 300°C 
Nebulizer: 30 psig 
Ref nebulizer: 1 psig 
Data Acquisition: MS only mode. For Positive Polarity: range 103-1500 m/z 
For Negative Polarity: Range 115-1000 m/z 
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3.3.4.2. Isolation of Panduratin A Compound from B. rotunda Crude Extract 
  A quantity of 2.67 g B. rotunda crude (BR) was dissolved in 1 mL acetone (Merck 
AR Grade, Malaysia), solvent. The resulting concentrated crude alcoholic extract solution 
was then mixed with 5 g silica gel (Silicycle, Ultrapure Silica Gel, Canada) and dried using 
rotary evaporator to form sample powder. The sample powder obtained was subjected to 
dry-pack column chromatography (CC) containing 47 g of silica gel. The 
fractionation/isolation step was based on gradient elution method and the solvent system 
used was Hexane-Ethyl acetate (Fisher Scientific AR Grade, UK). A total of 11 fractions 
afforded (Figure 1). A Thin Layer Chromatography (Merck, Silica gel 60 F254, Japan) 
experiment of the 11 fractions versus Paduratin A standard (98% purity, China) was carried 
out using Hexane-Ethyl acetate (Fisher Scientific AR Grade, UK) at ratio 95:5. Fraction 
BR-3 was prepared in high and low concentrations (10 and 1 mg/ml respectively) using 
acetone solvent (AR grade, Merck) for TLC profiling. Pure crystals (96.6%) of Panduratin 
A were obtained as confirmed by High Performance Liquid Chromatography (HPLC) 
report according to the following formula, 
% Purity = Peak Area of Panduratin A/ (Total Peak Area-Peak Area of solvent) 
The mass of the isolated panduratin A was determined by LCMS using METLIN 
DATABASE.  
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3.3.4.3. Yield of Panduratin A compound 
A quantity of 28 g of B. rotunda alcoholic extract was fractionated by dry packed 
column chromatography as previously mentioned. A column of 5 cm was used to 
fractionate 10 g of the crude extract giving a yield of 2.87g. Pale yellow crystals of pure 
panduratin A were obtained and prepared for evaluating the hepatoprotective activity of 
Panduratin A in vivo.  
 
Figure 3.1: Flow Chart fractionation of B. rotunda (BR) crude extract using dry pack 
column chromatography (CC). H: Hexane, EA: Ethyl acetate, TLC: Thin Layer 
Chromatography, HPLC: High Performance Liquid Chromatography. 
 
 
3.3.4.4. Isolation of Germacrone Compound from C. longa Crude Extract 
A quantity of 9.5 g of C. longa crude sample was dissolved in 1 ml acetone solvent (Merck 
AR Grade, Malaysia). The resulting solution was mixed with 50 g of silica gel (Silicycle, 
Ultrapure Silica Gel, Canada) and dried using rotary evaporator to form sample powder. 
B. rotunda (BR) crude (2.67 g) 
Dry-Pack CC 
BR1 
95:5  
H: EA
BR2 
9:1    
H: EA
BR3 
99:1 
H:EA
Panduratin A                  
TLC and HPLC
BR4 
99:1 
H:EA
BR5 
99:1 
H:EA
BR6 
99:1 
H:EA
BR7 
99:1 
H:EA
BR8 
99:1 
H:EA
BR9 
99:1 
H:EA
BR10 
99:1 
H:EA
BR11 
99:1 
H:EA
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The sample powder obtained was subjected to column chromatography (CC) containing 
silica gel. The amount of silica gel (150 g) used was based on the ratio of 1 g of crude 
extract to 15 g of silica gel. The fractionation/ isolation step was based on gradient elution 
method and the solvent system used was Petroleum ether- Ethyl acetate (Fisher Scientific 
AR Grade, UK). A total of 18 fractions afforded (Figure 3-2). A Thin Layer 
Chromatography (TLC) (Merck, Silica gel 60 F254, Japan) experiment of the 18 fractions 
versus Germacrone standard was carried out using Hexane- Ethyl acetate (Fisher Scientific 
AR Grade, UK) at ratio 95: 5. Fractions 1-4 (CL-1-4) were combined and dried using 
rotary evaporator and weighed using analytical balance.  
Purification of Germacrone from CL-1-4 
2.65 g of the combined fraction sample (CL-1-4) was dissolved in 1 ml hexane 
solvent (Fisher Scientific AR Grade, UK). The sample was subjected to column 
chromatography (CC) containing silica gel (Silicycle, Ultrapure Silica Gel, Canada). The 
amount of silica gel (27 g) was based on the ratio of 1 g of crude extract to 10 g of silica 
gel. Hexane- Ethyl acetate solvent system was used. A total of 21 fractions were afforded 
(Figure 3-2) from the fractionation. A thin Layer Chromatography (TLC) experiment was 
performed using Hexane- Ethyl acetate (Fisher Scientific AR Grade, UK) at ratio 95: 5 on 
all the fractions. TLC was observed under UV light at 254 nm and was stained with 15% 
Concentrated Sulphuric acid (Fisher Scientific AR Grade, UK) in ethanol (Fisher Scientific 
96%, Malaysia) to confirm the presence of Germacrone. The mass of the isolated 
Germacrone was determined by LCMS and the library used in identification was METLIN 
DATABAS. 
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Figure 3.2: Flow Chart fractionation of C. longa (CL) crude extract. CC: Column 
Chromatography.  H: Hexane, EA: Ethyl acetate, PE: Petroleum Ether, EA: Ethyl acetate. 
TLC: Thin Layer Chromatography. 
C. longa (CL )crude extract (9.5 g)
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99:1 
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99:1 
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99:1 
PE:EA
CL 9-10 
99:1 
PE:EA 
CL11 
99:1 
PE:EA
CL12-17 
99:1 
PE:EA
CL 18 
99:1 
PE:EA
Combined fractions CL 1- CL4 (2.65 g)
Further purification
1-5  
100 H
6 - 15      
85:5  H: 
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16 - 20 
95:5 H: 
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21 
80:20 H: 
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TLC of fractions CL1 – CL18 
versus Germacrone standard 
TLC of 21 fractions versus 
Germacrone standard 
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3.3.5. In vitro Protective Activity of Panduratin A and Germacrone against TAA-Induced 
Oxidative Damage in WRL-68 
 
3.3.5.1. DPPH Scavenging Activity of Panduratin A 
The antioxidant capacity of the isolated compound PA was examined first by using 
1,1-diphenyl-2-picrylhydrazyl radical (DPPH) stable free radical scavenging assay as 
previously described in section 3.2.1 compared to Ascorbic acid as a standard. 
 
3.3.5.2. Cell Culture 
Human normal liver cell line (WRL-68) was purchased from American Type 
Culture Collection ATCC (Rockville, MD, USA) and allowed to grow in RPMI-1640 
(Sigma-Aldrich, UK) (Sato et al., 2004) formulated with 10 % (v/v) FBS (J R Medical, Inc, 
USA) and penicillin-streptomycin solution of concentration1% (v/v) (Sigma-Aldrich, UK). 
WRL-68 cell line was grown and maintained at 37° C, 5 % CO2 incubator (NuAire, 
Plymouth, USA). 
 
3.3.5.3. Determination of the IC50 Dose of TAA Cytotoxicity 
To induce cell oxidative damage by TAA and to determine the dose of TAA that 
kills 50 % of cells (IC50), WRL-68, normal cells (Passage 24) were seeded onto 96-well 
sterile plates with flat bottoms (Jet Biofil, China) for tissue culture in 100 µL of RPMI-
1640 containing 10% FBS with density 3000 cells/ well. Cells were incubated at 37oC and 
5% CO2 for 24 hours. An amount 10 µL of different concentrations 0.03, 0.04, 0.05 g/mL 
TAA was added to the cells according to (Sarkar & Sil, 2007) with slight modification. 
TAA was prepared by dissolving each dose separately in sterile distilled water. The cells 
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were designed (Table 3.3) in 4 separate experiments for 30, 60, 90 and 120 minutes, each in 
triplicate and the cell viability was calculated every time by Trypan blue dye (Sigma, UK) 
exclusion test MTT (Bove et al., 2001) after 30, 60, 90 and 120 minutes of incubation, 
while the absorbance was read at 570 nm. The percentage of cell viability was calculated 
by the following formula, 
% Cell viability = [(O.D TAA-treated cells / O.D Sterile-D.W-treated cells) X 100] 
 
Table 3.5: Experimental design (x4) for determining IC50  of TAA 
Group Treatment in 100 µL RPMI-1640 
 
Control 
   
 
TAA 0.03 g/mL 
   
 
TAA 0.04 g/mL 
   
 
TAA 0.05 g/mL 
   
TAA: Thioacetamide, D.W: Distilled water 
 
3.3.5.4. Evaluation of Cytotoxicity of Panduratin A and Germacrone Compounds 
To test Panduratin A and Germacrone compounds for their cytotoxicity in WRL-68, 
the compounds were prepared in concentrations 1, 10 and 100 µg/ mL (Sarkar & Sil, 2007) 
10 μL sterile 
D.W 
10 μL sterile 
D.W 
10 μL sterile 
D.W 
10 μL TAA 10 μL TAA 10 μL TAA 
10 μL TAA 10 μL TAA 10 μL TAA 
10 μL TAA 10 μL TAA 10 μL TAA 
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by complete dissolving of each dose separately in 2.5% DMSO and then adjusting the 
volume to I mL RPMI-1640. Cells were seeded in 200 µL of RPMI-1640 containing 10% 
FBS and 1% penicillin-streptomycin solution with density 3000 cells/well in 96-well plate 
and incubated at 37oC and 5% CO2 for 24 hours. Cells were then treated with 10 µL of the 
mentioned concentrations and designed in 3 separate experiments for 24, 48 and 72 hours. 
Twenty four hours after each period, 10 μL of the yellow MTT (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide, a tetrazole) was added into each well and re-
incubated for 4 hours under the same conditions. The purple formazan colour in the 
mitochondria of the cells results from the reduced MTT indicating living cells (Liu et al., 
1997). Directly after incubation, the contents of all the wells were removed followed by the 
addition of 100 μL of DMSO (Fisher Medical, UK) to each well to read the absorbance at 
570 nm using energy trend x340 ELISA Audience (Bio-Tek Equipment, Inc., Winooski, 
VT, USA). Each experiment was demonstrated in triplicate and the % cell viability was 
calculated.  
 
3.3.5.5. Evaluation of the Protective Effect of Panduratin A and Germacrone Compounds 
against TAA-Cytotoxicity in WRL-68 Cell Line 
Cells were seeded in 200 µL RPMI-1640 containing 10% FBS and 1% penicillin-
streptomycin solution with density 3000 cells/well in 96-well plate and incubated at 37oC 
and 5% CO2. After 24 hours, cells were treated with a single dose of 0.04 g/mL TAA (10 
µL) except Normal control group cells. All cells were incubated for one hour and then 
Silymarin as a reference drug, Panduratin A and Germacrone compounds were added in the 
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prepared concentrations 1, 10 and 100 µg/mL. Each dose of the mentioned compounds and 
Silymarin was prepared by dissolving the required dose in 2.5% DMSO and adjusting the 
volume to 1 mL using RPMI-1640. Cells were designed in 3 separate experiments each in 
triplicate and incubated for 24, 48 and 72 hours. The cell viability test was performed for 
all the cells and the absorbance was read at 570 nm to calculate the % cell viability. 
Table 3.6: Experimental design for the In vitro hepatoprotective activity of Panduratin A 
and Germacrone compounds compared to Silymarin 
Group Toxic substance 
(TAA 0.04 mg/mL) 
Treatment 
Normal control _ _ 
Toxin control 10 µL _ 
Si1  
1µg/mL Silymarin 10 µL 10 µL 
Si10 
10 µg/mL Silymarin 10 µL 10 µL 
Si100 
100 µg/mL Silymarin 10 µL 10 µL 
Pa1 
1 µg/mL Panduratin A 10 µL 10 µL 
Pa10 
10 µg/mL Panduratin A 10 µL 10 µL 
Pa100 
100 µg/mL Panduratin A 10 µL 10 µL 
Ge1 
1 µg/mL Germacrone 10 µL 10 µL 
Ge10 
10 µg/mL Germacrone 10 µL 10 µL 
Ge100 
100 µg/mL Germacrone 10 µL 10 µL 
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3.3.5.6. Assessment of MDA and SOD 
To evaluate the protective effect of Panduratin A and Germacrone against TAA-
induced oxidative damage, the following experiment was conducted to assess the level of 
the antioxidant enzyme SOD and MDA resulting from oxidative damage in the cell lysate 
collected from all samples. WRL-68 cells were seeded and incubated with 10 µL TAA 
(0.04 g/mL) and then 10 µL of  Silymarin, Panduratin A and Germacrone compounds was 
added, each in the concentrations (1, 10, 100 μg/mL) as mentioned previously. After 72 
hours of incubation at 37oC and 5% CO2, all the cells were washed twice with 300 μL 
Phosphate Buffered Saline (PBS), pH 7.4. The cells were detached using a sterilized 
scrapper, lysed in 25 mmol/L Tris-HCl lysis buffer, sonicated on ice (10 seconds pulse) and 
then centrifuged at 13000 x g for 15 minutes to remove the cell debris. The resulting cell 
lysates were collected and kept at -20oC for assaying SOD and MDA following the 
instructions in the kit manuals of Cayman kits, USA (Cat. # 706002 for SOD, and # 
10009055 for MDA).  
 
3.3.6. In vivo Hepatoprotective Effect of Panduratin A against Induced Liver Damage in Rats 
3.3.6.1. Animals 
Thirty healthy male Sprague Dawley rats (180-250 g) were used in the experiment.  
All rats were kept at 25 ± 3°C in an animal room and the humidity was maintained at 40-
60%, the animals were given tap water and standard pellet diet. During the experiments, 
animals were treated following the criteria outlined in the “Guide for the Care and Use of 
Laboratory Animals” prepared by the National Academy of Sciences and published by the 
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national Institute of health. The approval of the study was processed by the Ethics 
Committee for Animal Experimentation, Faculty of Medicine, University of Malaya, 
Malaysia PM/28/08/2009/MAA. 
 
3.3.6.2. Evaluation of Hepatoprotective Activity of Panduratin A Compound 
Animals were at random separated into 6 groups of 5 rats each. Group 1 Rats 
(Normal group) were given 10% Tween-20 daily by oral administration and sterile distilled 
water (1 mL/kg) by intraperitoneal injection 3 times every week. TAA and Silymarin were 
prepared as mentioned earlier in our study. Groups 2–5 were intraperitoneally injected by 
TAA (200 mg/kg) three times per week to induce liver cirrhosis. Group 2 rats of (group of 
cirrhosis control) were by mouth administered a daily dose of 5 mL/kg, 10% Tween-20 
daily. Group 3 rats (Silymarin-treated group) were by mouth administrated Silymarin (50 
mg/kg) everyday. Rats of Groups 4, 5 and 6 (groups treated with different doses of 
Panduratin A) were by mouth administered PA compound at everyday amounts of 5 mg/kg, 
10 mg/kg and 50 mg/kg (Hamed et al., 2011; Lee et al., 2003), respectively (Table 3.7) . At 
the end of the 4 weeks, the animals were allowed to fast for 24 h after and sacrificed under 
ketamine (30 mg/kg, 100 mg/mL) and xylazil (3 mg/kg, 100 mg/mL) sedation (Fatemi, et 
al., 2010). Blood was taken out through the jugular vein and gathered for biochemical tests. 
After excising the livers of animals, they were cleaned in ice normal saline, weighed, 
properly and analyzed for any possible pathological changes in the gross and then gathered 
for histopathology study. After normal saline washes, 50 mM cold potassium phosphate 
buffer (pH 7.4) was used to prepare liver tissue homogenates (10% w/v). Liver samples 
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were then homogenized using a teflon homogenizer (Polytron, Heidolph RZR 1, Germany). 
A refrigerated centrifuge (Heraeus, Germany) was used to centrifuge liver tissue 
homogenates at 4500 rpm for 15 minutes at 4°C and the collected supernatant was divided 
into aliquots. 
 
Table 3.7: Animal experimental design for the in vivo hepatoprotective effect of 
Panduratin A 
Group Number of animals 
Intraperitoneal 
injection (three 
times/week) 
Oral administration 
(5mL/kg) 
Durations 
(weeks) 
Normal control 5 Sterile distilled water (1mL/kg) 10% Tween 20 4 
Cirrhosis control 5 TAA 10% Tween 20 4 
Reference control 5 TAA Silymarin 50mg/kg 4 
Low dose PA  
 5 TAA 
Panduratin A 
5mg/Kg 4 
Medium dose PA 5 TAA Panduratin A 10mg/kg 4 
High dose PA 5 TAA Panduratin A 50mg/kg 4 
 
3.3.6.3. Biochemical Study 
Samples of blood from all animals were collected into gel-activated tubes for the 
evaluation of particular liver markers as previously explained in section 3.3.3.3.  
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3.3.6.4. Liver Malondialdehyde (MDA) Level 
To evaluate the degree of lipid peroxidation in liver, malondialdehyde level was 
determined in the liver tissue homogenate of animals using thiobarbituric acid according to 
the company's guidelines (Cayman packages, Sigma cat # 10009055, Appendex II, p. 199) 
and protein concentration was assessed by Lowry et al. (1951) method as mentioned 
previously. 
 
3.3.6.5. Antioxidant Enzymes (SOD, CAT and GPx) Assessment 
The antioxidant enzymes, superoxide dismutase (SOD), catalase (CAT) and 
Glutathione peroxidase (GPx) were assayed in the liver tissue homogenates by Cayman 
packages according to the company's guidelines (Cayman) as previously mentioned 
(Appendix II, P. 205 and 212) 
 
3.3.6.6. Histopathology  
Liver samples collected from all experimental animals were prepared for H&E and 
Masson’s Trichrome staining as previously mentioned in sections 3.3.3.1 and 3.3.3.2. 
 
3.3.6.7. Immunohistochemistry 
Sections of liver tissues were prepared and processed as previously mentioned in 
section 3.3.3.11.  
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3.3.7. Statistical Analysis  
Statistical analysis of the results was performed by SPSS (Version 18, SPSS Inc., 
Chicago, IL, USA). Data were analyzed by following one-way ANOVA and Tukey Post-
Hoc Test analysis. Statistically, P<0.05 value was considered significant on comparing the 
data between two groups. All values were mentioned as Mean ± SEM. 
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CHAPTER IV 
RESULTS 
4.1. Antioxidant Properties of B. rotunda and C. longa Extracts 
4.1.1. The Scavenging Activity of the Crude Extracts to DPPH 
The percentage DPPH inhibition of B. rotunda (BR) and C. longa (CL) extracts are 
illustrated in Figure 4.1. Results showed that B. rotunda rhizome extract exhibited IC50 
68.33 ± 1.67 µg/mL which was significantly higher than that of C. longa extract (10.81 ± 
0.60 µg/mL) and the standards Ascorbic acid and Trolox (4.07 ± 0.88 and 9.32 ± 0.40 
µg/mL respectively). In addition, IC50 of CL (10.81 ± 0.60 µg/mL) was found to approach 
the value of Trolox (9.32 ± 0.40 µg/mL). Results indicate that the ability of BR to scavenge 
DPPH is lower than that of CL which has better scavenging activity that approaches the 
capacity of the standard Trolox. 
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Figure 4.1: (a) Ascorbic acid standard curve (b) Trolox standard curve (c) Antioxidant 
activity of the B. rotunda (BR) and C. longa (CL) extracts compared with the standards, 
Ascorbic acid, and Trolox.  
 
 
4.1.2. FRAP capacity of the Crude Extracts 
As illustrated in Figure 4.2, the ferric reducing antioxidant power (FRAP) of C. 
longa extract was significantly higher (P<0.001) (1738.22 ± 5.25 mmol FeII/mg) than that 
of B. rotunda (BR) extract which measured 282.30 ± 3.35 mmol FeII/mg. The measured 
value from both plant extracts were sigificantly lower than the ferric reducing power of the 
standard Ascorbic acid (1888.33 ± 6.94 mmol FeII/mg respectively) but comparable to the 
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reference drug silymarin, which read 603.56 ± 4.34 mmol FeII/0.1mg. Based on these 
readings, it is reasonable to extrapolate that CL extract has high antioxidant activity and BR 
extract must be containing sufficient acceptable level of anti-oxidant activity, supporting its 
free radical scavenging property, in helping the liver maintain its status quo. 
 
 
 
Figure 4.2: (a) FRAP standard curve (b) Ferric reducing power (FRAP) of the B. rotunda 
(BR) and C. longa (CL) extracts compared with the standard Ascorbic acid as well as the 
standard drug Silymarin. Values were expressed as Mean ± SEM. *P< 0.001 compared to 
silymarin. #P<0.001 compared to BR. **P< 0.001 compared to Ascorbic acid 
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4.1.3. TPC of Crude Extracts 
Figure 4.3 shows the total phenolic content of 1 mg of BR and CL extracts 
compared to 0.1 mg Silymarin. Results showed that TPC of BR and CL extracts were 
significantly higher (P<0.001) (338.12 ± 7.51, 485.44 ± 14.30 μg GAE/mg extract 
respectively) than the TPC of 0.1 mg Silymarin (128.40 ± 2.81 μg GAE/0.1 mg extract). 
Moreover, there was no significant difference between the TPC value of CL and BR. These 
results show that both plants extracts have high phenolic content that may explain their 
hepatoprotective activity. 
 
 
Figure 4.3: Total phenol content (TPC) of the B. rotunda and C. longa extracts compared 
with the standard drug Silymarin in gallic acid equivalent. Values were expressed as Mean 
± SEM. *P<0.001 compared to Silymarin. 
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4.2. Acute Toxicity of Crude Extracts 
Following administration of B. rotunda and C. longa crude extracts, all animals 
were alive and did not show any signs of toxicity even at the highest dose used (5 g/mL). 
The physical observations indicated no signs of changes in their skins and furs, eyes and 
mucus membranes, behavior patterns, tremors, salivations, diarrhea occurrences and sleep. 
The body weight of the treated male and female rats increased gradually but were not 
significantly different as compared to those of the control rats (Table 4.1). No significant 
differences in the clinical observations, serum biochemistry (Tables 4.2 and 4.3) and 
histopathology of liver and kidney (Figure 4.4) were detected between control and treated 
groups.   
Table 4.1: Effect of B. rotunda and C. longa extracts on the body weights of rats measured 
from the acute toxicity test 
Group Body weight on Day 0 (g) 
Body weight on 
 Day 14 (g) 
Vehicle 
 (5 ml/kg) 196.37 ± 7.36 202.21 ± 9.54 
Low dose B. rotunda 
(2g/kg) 199.28 ± 10.20 216.12 ± 11.20 
High dose B. rotunda 
(5g/kg) 195.10 ± 6.02 214.60 ± 3.63 
Low dose C. longa 
(2g/kg) 191.83 ± 3.31 210.33 ± 6.54 
High dose C. longa 
(5g/kg) 199.00 ± 5.97 218.33 ± 7.62 
Data were recorded as mean ± SEM. No significant changes among the groups. Significant 
value was at P<0.05.
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Table 4.2: Effect of B. rotunda and C. longa extracts on the renal function measured from the acute toxicity test on rats. 
Dose Sodium 
(mmol/L) 
Potassium 
(mmol/L) 
Chloride 
(mmol/L) 
Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
Vehicle 
 (5 ml/kg) 
138.25 + 0.45 5.03 + 0.19 104.03 + 0.15 5.63 + 0.41 50.18 + 1.34 
Low dose B. 
rotunda (2 g/kg) 
137.65 + 0.43 5.21 + 0.16 102.61 + 1.22 4.96 + 0.43 48.97 + 0.81 
High dose B. 
rotunda (5 g/kg) 
137.21 + 0.51 4.89 + 0.15 102.67 + 0.76 5.93 + 0.39 48.60 + 1.80 
Low dose C. longa  
(2 g/kg) 
143.31 + 2.11 5.14 + 0.39 103.46 + 2.04 4.97 + 0.58 39.00 + 2.71 
High dose C. longa 
(5g/kg) 
140.67 + 2.67 5.09 + 0.40 103.70 + 1.52 5.27 + 0.52 38.82 + 3.14 
The values were expressed as mean ± SEM.  There were no significant differences between the three groups. Significant value 
was at P<0.05. 
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Table 4.3: Effect of B. rotunda and C. longa extracts on the liver function measured from the acute toxicity test on rats. 
Dose Total protein 
(g/L) 
Albumin  
(g/L) 
TB 
 (µmol/L) 
AP 
 (IU/L) 
ALT 
 (IU/L) 
AST 
 (IU/L) 
GGT 
(IU/L) 
Vehicle 
(5 ml/kg) 
 
71.37 + 1.44 
 
11.36 + 0.53 
 
1.91 + 0.17 
 
134.78 + 9.57 
 
53.05 + 3.27 
 
153.65 + 9.35 
 
4.91 + 0.93 
Low dose 
B. rotunda 
(2 g/kg) 
71.47 + 0.52 11.61 + 0.34 2.18 + 0.16 133.37 + 8.63 51.90 + 1.33 156.07 + 3.56 5.00 + 1.23 
High dose  
B. rotunda 
(5 g/kg) 
71.81 + 1.03 11.72 + 0.16 1.88 + 0.21 135.13 + 6.52 52.27 + 3.25 
 
155.00 + 5.35 
 
5.32 + 1.07 
Low dose  
C. longa  
(2g/kg) 
71.17 + 1.28 12.76 + 0.58 2.15 + 0.16 66.90 + 5.40 39.17 + 3.16 62.48 + 2.63 4.08 + 0..45 
High dose  
C. longa  
(5g/kg) 
69.17 + 1.85 12.26 + 0.64 1.85 + 0.46 70.08 + 11.12 34.50 + 2.91 55.17 + 4.83 4.67 + 0.33 
TB: Total bilirubin; AP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: 
Gamma-Glutamyl Transferase.  The values were expressed as mean ± SEM.  There were no significant differences between the 
three groups. Significant value was at P<0.05. 
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Figure 4.4: Histological sections (H&E) of livers (right column) and kidneys (left column) 
obtained from the rats in the acute toxicity test. Rat with the kidney and liver shown in (a) 
and (b) was treated with 5 ml/kg vehicle (10% Tween 20). Rat with the kidney and liver 
shown in (c) and (d) was treated with 2 g/kg (5 ml/kg) dose of the B. rotunda extract. Rat 
with the kidney and liver shown in (e) and (f) was treated with 5 g/kg (5 ml/kg) dose of the 
B. rotunda extract. Rat with the kidney and liver shown in (g) and (h) was treated with 2 
g/kg (5 ml/kg) dose of the C. longa extract.  Rat with the kidney and liver shown in (i) and 
(j) was treated with 5 g/kg (5 ml/kg) dose of the C. longa extract. There was no significant 
difference in the structures of the liver and kidney between the treatment and control 
groups. (Original magnification x20) 
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4.3. Hepatoprotective Effect of B. rotunda and C. longa Extracts on Liver 
Cirrhosis 
4.3.1. Body Weight and Liver Index 
Before sacrifice, the total body weight of each rat was measured. Rats from the 
normal control group followed a normal growth pattern and obtained a normal weight gain 
from 184.33 ± 2.08 g on Day 0 reaching 346.51 ± 3.57 g after 8 weeks experimental period. 
Rats of cirrhosis group had retardation of their growth and their body weight decreased 
significantly (P<0.05) than other groups. When the body weights were factored in, rats 
from cirrhosis control group measured the highest liver index. The rats treated with high 
dose of B. rotunda extract (500 mg/kg), attained weights equivalent to Silymarin-treated 
rats, while the rats treated with high dose C. longa extract attained weights equivalent to 
those of normal control group. Further, the rats treated with the low dose (250 mg/kg) B. 
rotunda and C. longa acquired increase of body weight more than those of cirrhosis control 
group but not like those animals of silymarin-treated group and high dose B. rotunda or C. 
longa-treated groups (Table 4.4) which gained better body weight. These findings suggest 
that high dose B. rotunda and C. longa could be choicest since their attenuating efficacy to 
cirrhosis progression was as effective as Silymarin. 
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Table 4.4 Effect of B. rotunda and C. longa crude extracts on the liver index measurements from the rats at the end of the 8 
week study 
Group Initial Body Weight (gm) 
Final Body 
Weight (gm) 
Liver Weight 
(gm) 
Spleen 
Weight (gm) 
Liver Index  
(%) 
Normal control 
(10% Tween 20, 5ml/kg) 
184.33 ± 2.08 346.51 ± 3.57 9.70 ± 0.12 0.57 ± 0.01 2.79 ± 0.15 
Cirrhosis control 
(TAA i.p, 200mg/kg) 
180.33 ± 0.33 183.03 ± 1.64** 9.44 ± 0.53 0.54 ± 0.01 5.17 ± 0.04** 
Reference control  
(Silymarin 50 mg/kg) 
227.5 ± 9.73 346.70 ± 2.53* 10.28 ± 0.47 0.61 ± 0.17 2.97 ± 0.25* 
Low dose B. rotunda 
(250 mg/kg) 
186.83 ± 2.70 245.92 ± 2.06* 10.03 ± 0.38 0.53 ± 0.13 3.93 ± 0.38# 
High dose B. rotunda 
(500 mg/kg) 
256.33 ± 10.81 376.40 ± 4.01* 9.71 ± 0.57 0.60 ± 0.01 2.59 ± 0.25* 
Low dose C. longa 
(250 mg/kg) 
187.00 ± 2.92 249.17 ± 14.89* 8.80 ± 0.29 0.55 ± 0.01 3.58 ± 0.19* 
High dose C. longa 
(500 mg/kg) 
216.17 ± 10.08 351.00 ± 19.73* 9.48 ± 0.19 0.68 ± 0.01 2.74 ± 0.15* 
Data were expressed as Mean ± SEM. Means among groups (n = 6 rats/group) *P<0.001compared to cirrhosis control. 
**P<0.001compared to normal control group with. #P<0.01 compared to cirrhosis control group. 
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4.3.2. Gross anatomy and histopathology  
Figures 4.5 and 4.6 respectively depict the gross appearances and the H&E stained 
sections of liver samples from the experimental groups 1-7. Grossly, the livers from the 
normal control group rats appeared in reddish color had smooth surfaces and did not show 
any sign of nodules. The histological examination showed normal liver architecture with 
normal plates of hepatocytes separated by sinusoidal capillaries and central vein.  In 
cirrhosis control group, the liver appeared congested with numerous micro and macro- 
nodules, lost its normal architecture by the presence of regenerating nodules that were 
separated by fibrous septae extending from the central vein to potal triad. In addition, the 
fibrous septae was accompanied by severe proliferation of bile duct and heavy invasion of 
inflammatory cells. The cirrhotic nodules showed thick purple colored bundles of collagen 
fibers. The livers of the high doses of B. rotunda extract and C. longa extract showed 
relatively minor micro-nodules, lesser amount of fibrous septae development and 
expansion and an increase in the extension of normal hepatic parenchyma compared to the 
silymarin-treated group (reference control),. In contrast, the livers of the low dose B. 
rotunda and C. longa groups were occupied by lesser macro-nodules and lesser fibrotic 
nodules than those of the reference group, but the improvements were not as much as those 
seen in high dose groups of both plant extracts. These results based on the visual 
evaluations provided further independent confirmation that the applied B. rotunda and C. 
longa extracts were effectively protecting the liver against the progression of cirrhosis, but 
in a dose-dependent manner. 
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Figure 4.5: Gross images showing macroscopic appearances of the livers sampled from 
rats in different experimental groups. (a) The liver of a normal control rat exhibited regular 
smooth surface. (b) The liver of a hepatotoxic rat depicted numerous irregular whitish 
micro- and macronodules on its surface and a large area of ductular cholangiocellular 
proliferation (white arrow) embedded within fibrosis. (c) The liver of a hepatoprotective rat 
treated with silymarin showed relatively smooth surface. (d, f) Livers of rats treated with 
250 mg/kg of the B. rotunda (BR) and C. longa (CL) extracts respectively illustrated nearly 
smooth surface with fewer granules (black arrow). (e, g) Livers of rats treated with 500 
mg/kg of the B. rotunda and C. longa extracts respectively had normal smooth surface. 
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 Figure 4.6: Histopathological sections (H&E) of livers sampled from rats in different 
experimental groups. (a) Normal histological structure and architecture were seen in livers 
of a normal control rat. (b) Severe structural damage, formation of pseudolobules with 
thick fibrotic septa and proliferation of bile duct (white arrow) were present in the liver of a 
cirrhotic rat. (c) Minor inflammation but no fibrotic septa was depicted in the liver of a 
hepatoprotected rat treated with silymarin. (d, f) Partially preserved hepatocytes and 
architecture with mild area of necrosis and fibrotic septae (black arrow) existed in the liver 
of the rats treated with 250 mg/kg of the B. rotunda (BR)and C. longa (CL) extracts 
respectively. (e, g) Highly preserved hepatocytes and architecture with very small areas of 
minor fibrosis were observed in the liver of the rats treated with 500 mg/kg of the B. 
rotunda and C. longa extracts respectively. (Original magnification of H&E stain 20x). 
 
4.3.3. Cell loss and survival 
The results concerning the normality of the hepatocytes were illustrated in Figure 
4.7 for rats of all the groups According to the data, the administration of TAA was seen to 
significantly decrease the number of normal liver cells from about 94% measured from the 
livers of the normal rats to about 11% measured from the livers of the cirrhotic rats of the 
cirrhosis control group. In the low dose B. rotunda and C. longa (250 mg/kg) treatment, the 
population of the normal cells was higher, about 65% and 71% respectively. But, the 
treatment with the high dose B. rotunda and C. longa (500 mg/kg) maintained much higher 
number of normal cells, about 90% and 91% respectively, which was nearly equal to those 
g 
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obtained from the silymarin-treated rats (93%) and comparable in the same manner to the 
normal rats. Figure 4.8 shows the difference between normal and dead hepatocytes. 
 
Figure 4.7: Effect of B. rotunda (BR) and C. longa (CL) crude extracts on % cell 
normality. Data are expressed as mean ± SEM.  Means among groups (n = 6 
rats/group) show significant difference, **P< 0.001 compared to normal control 
group, *P< 0.001 compared to cirrhosis control group. Normal control (distilled 
water. Cirrhosis control (TAA 200 mg/kg). Reference control (Silymarin 50 
mg/kg). Low dose BR and CL (250 mg/kg). High dose BR and CL (500 mg/kg). 
 
Figure 4.8: Liver section showing the difference between normal hepatocytes 
(white arrows) and dead hepatocytes (black arrows). (H&E stain Original 
magnification 40x). 
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4.3.4. Masson’s Trichrome Staining 
To measure the degree of fibrosis in the liver of experimental animals, the stain of 
Masson’s Trichrome was used to measure the degree of deposition of collagen fibers as 
shown in Figure 4.9. Liver sections of normal control group rats were normal with no signs 
for collagen deposition. Sections of cirrhosis control group rats showed increased collagen 
fibers deposition and congestion was observed clearly around the central vein showing high 
degree of fibrosis. Liver tissues from the group treated with Silymarin revealed minor 
collagen deposition indicating minor fibrosis. The central vein showed moderate 
congestion in the livers of the rats treated with low dose B. rotunda and C. longa extracts as 
indicated by moderate deposition of collagen fibers. The central vein was surrounded by 
mild collagen deposition in the liver samples of the high dose B. rotunda and C. longa 
extracts-treated. This evaluation of the degree of fibrosis confirms the previous findings 
that treatment with B. rotunda or C. longa extracts might suppress liver fibrosis in the 
animals. 
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Figure 4.9: The staining of Masson’s Trichrome of representative liver samples of all the 
experimental groups. (a) The liver of normal rats showed absence of of collagen deposition 
c d 
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in livers from a normal control rat. (b) High degree of fibrosis with intensive collagen 
deposition (arrow) was noticed in the livers from a cirrhosis rat. (c) Minor deposition of 
collagen fibers in the liver of Silymarin-treated group. (d, f) The central vein of the liver of 
rats treated with low dose B. rotunda (BR) and C. longa (CL) extracts respectively showed 
moderate congestion with moderate collagen deposition. (e, g) Minor collagen deposition 
was seen in the livers of rats treated with high dose B. rotunda and C. longa extracts 
respectively (Original magnification ×20). 
 
4.3.5. Liver markers and lipid profile 
Liver function of each rat was measured by determining the plasma levels of 
specific liver enzymes and lipid profile, and the results were presented in Tables 4.5, 4.6 
and 4.7. According to the data shown in Table 4.5 and 4.6, the liver damage due to TAA 
significantly elevated the levels of specific liver enzymes AP, ALT, AST, GGT, LDH, 
bilirubin and Prothrombin time (P< 0.001) and significantly declined the protein and 
albumin levels in the cirrhotic rats of cirrhosis control group as compared with those 
measured from all the other groups.  Similarly, the lipid profiles in the cirrhotic rats altered 
significantly such that the cholesterol, LDL and triglycerides levels were higher and the 
HDL level was lower (Table 4.7). The high dose B. rotunda and C. longa (500 mg/kg) 
treatment resulted in the readings on the biochemical markers that were comparable to 
those of the normal control and the silymarin-treated (50 mg/kg) groups and better than the 
readings obtained from the treatment with the low dose B. rotunda and C. longa (250 
mg/kg) treatment groups. These data further supported the qualitative gross, anatomical 
histopathological findings, the quantitative cell counts, presented above, and demonstrated 
that the effects of the toxicity induced by TAA on the liver function can effectively be 
counterbalanced by the positive effects of the B. rotunda and C. longa extracts treatment, 
but in a dose dependent manner. 
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Table 4.5: Effect of B. rotunda and C. longa crude extracts on the plasma levels of specific liver enzymes measured from the 
rats at the end of the 8 week study. 
Group AP  (IU/L) 
ALT  
(IU/L) 
AST  
(IU/L) 
GGT  
(IU/L) 
LDH  
(IU/L) 
Normal control 
(10% Tween 20, 5ml/kg) 79.28 ± 0.58 30.57 ± 1.51 70.35 ± 0.21 3.08 ± 0.08 490.97 ± 3.9 
Cirrhosis control 
(TAA i.p, 200mg/kg) 270.50 ± 4.88** 150.42 ± 2.60** 25.88 ± 2.99** 12.37 ± 0.26** 991.72 ± 5.00** 
Reference control  
(Silymarin 50 mg/kg) 83.85 ± 1.06* 31.62 ± 0.63* 70.35 ± 0.43* 2.95 ± 0.08* 546.33 ± 10.46* 
Low dose B. rotunda 
(250 mg/kg) 110.22 ± 0.49* 91.02 ± 1.61* 106.00 ± 2.59* 5.80 ± 0.17* 792.00 ± 3.51* 
High dose B. rotunda 
(500 mg/kg) 86.13 ± 0.56* 33.42 ± 0.56* 71.10 ± 0.78* 3.22 ± 0.07* 574.00 ± 5.34* 
Low dose C. longa 
(250 mg/kg) 98.98 ± 4.57* 85.62 ± 6.15* 84.48 ± 14.63* 8.08 ± 0.46* 564.17 ± 8.63* 
High dose C. longa 
(500 mg/kg) 90.10 ± 8.38* 62.48 ± 9.97* 84.30 ± 15.44* 3.93 ± 0.13* 688.73 ± 4.38* 
AP alkaline phosphatase; ALT alanine transferase; AST aspartate transferase; GGT gamma-glutamyl transferase; LDH lactate 
dehydrogenase. Data are expressed as mean ± SEM. Means among groups (n = 6 rats/group) show significant difference.. 
*P<0.001 compared with cirrhosis control group. **P<0.001 compared with normal control group. 
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Table 4.6: Effect of B. rotunda and C. longa crude extracts on the plasma protein, albumin and globulin levels and serum 
Prothrombin time measured from the rats at the end of the 8 week study 
Group Protein  (g/L) 
Albumin  
(g/L) 
Bilirubin  
(umol/L) 
PT  
 
Normal control 
(10% Tween 20, 
5ml/kg) 
76.58 ± 0.70 31.93 ± 0.64 1.20 ± 0.06 1.02 ± 0.01 
Cirrhosis control 
(TAA i.p, 200mg/kg) 59.92 ± 1.14
## 11.22 ± 0.33** 4.98 ± 0.12** 1.38 ± 0.02** 
Reference control  
(Silymarin 50 mg/kg) 75.82 ± 0.70
# 32.38 ± 0.88* 1.28 ± 0.07* 1.02 ± 0.00* 
Low dose B. rotunda 
(250 mg/kg) 63.37 ± 1.20 20.20 ± 0.20
# 2.85 ± 0.10* 1.28 ± 0.01# 
High dose B. rotunda 
(500 mg/kg) 75.10 ± 1.07
# 29.38 ± 0.28* 1.68 ± 0.05* 1.03 ± 0.00* 
Low dose C. longa 
(250 mg/kg) 53.50 ± 6.64 12.73 ± 1.66 2.57 ± 0.30* 1.26 ± 0.04* 
High dose C. longa 
(500 mg/kg) 75.08 ± 2.35
# 25.32 ± 3.36* 1.63 ± 0.25* 1.02 ± 0.01* 
PT; prothrombin time. Data are expressed as mean ± SEM. Means among groups (n = 6 rats/group) show significant difference,. 
*P<0.001 compared to cirrhosis control group. **P<0.001 compared to normal control group. #P<0.01 compared to cirrhosis 
control group. ##P<0.01 compared to normal control group. 
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Table 4.7: Effect of B. rotunda and C. longa crude extracts on the plasma lipid profiles measured from the rats at the end of 
the 8 week study. 
Group Cholesterol  (mmol/L) 
HDL  
(mmol/L) 
LDL  
(mmol/L) 
Triglycerides  
{mmol/L) 
Normal control 
(10% Tween 20, 
5ml/kg) 
1.42 ± 0.05 1.13 ± 0.04 0.13 ± 0.02 1.27 ± 0.03 
Cirrhosis control 
(TAA i.p, 200mg/kg) 3.22 ± 0.06** 0.53 ± 0.04** 2.50 ± 0.10** 2.83 ± 0.07** 
Reference control  
(Silymarin 50 mg/kg) 1.80 ± 0.37* 1.32 ± 0.04* 0.33 ± 0.03* 1.45 ± 0.04* 
Low dose B. rotunda 
(250 mg/kg) 2.00 ± 0.06* 0.62 ± 0.07 1.22 ± 0.07* 1.78 ± 0.03* 
High dose B. rotunda 
(500 mg/kg) 1.57 ± 0.05* 1.17 ± 0.05* 0.23 ± 0.02* 1.42 ± 0.05* 
Low dose C. longa 
(250 mg/kg) 2.23 ± 0.11* 0.82 ± 0.04# 1.28 ± 0.09* 1.83 ± 0.03* 
High dose C. longa 
(500 mg/kg) 1.78 ± 0.03* 1.30 ± 0.03* 0.33 ± 0.03* 1.47 ± 0.03* 
HDL; high density lipoprotein, LDL; low density lipoprotein. Data are expressed as mean ± SEM.  Means among groups (n = 6 
rats/group) show significant difference. *P<0.001 compared to cirrhosis control group. **P<0.001 compared to normal control 
group. #P<0.01 compared to cirrhosis control group. 
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4.3.6. Hepatic CYP2E1 Levels 
The results of the effect of B. rotunda and C. longa extracts on the hepatic 
cytochrome enzyme CYP2E1 are shown in Figure 4.10. Animals from cirrhosis control 
group had significantly (P<0.01) higher levels (2.85 ± 0.12 ng/ml) of CYP2E1 
compared with normal group (0.96 ± 0.36 ng/ml) and Silymarin-treated group (1.14 ± 
0.05 ng/ml). Low dose and high dose B. rotunda-treated rats showed significantly 
(P<0.01) lower levels (1.37 ± 0.15 and 1.10 ± 0.09 ng/ml respectively) of liver 
CYP2E1 when compared with the animals of cirrhosis control. On the contrary, no 
differences were noticed between the animals treated with the low dose C. longa and 
those treated with the high dose C. longa which had similar CYP2E1 levels (2.65 ± 
0.37 and 2.61 ± 0.27 ng/ml respectively). Also no significant difference was noticed 
between any of these groups and cirrhosis control group. 
 
4.3.7. Oxidative Stress Markers 
The markers of oxidative stress (MDA and nitrotyrosine, and urinary 8-OH-dG) are 
shown in Table 4.8. Generally, the cirrhotic livers of cirrhosis control group rats, had 
significantly higher levels of MDA, nitrotyrosine and 8-OH-dG (P<0.001) than those rats 
of the normal group and the plant extracts-treated groups. Particularly, the rats-treated with 
low dose and high dose B. rotunda extract, and low dose and high dose C. longa extract 
had significantly lower levels (P< 0.001) of liver MDA and nitrotyrosine and urinary 8-
OH-dG compared to cirrhosis control group. Moreover, no significant differences were 
detected between the plant extract-treated animals and Silymarin-treated animals in the 
tested biomarkers. These results suggest that treatment with B. rotunda and C. longa 
extracts may protect hepatic cells from further damage during liver injury. 
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Figure 4.10: (a) CYP2E1 standard curve. (b) Effect of B. rotunda (BR) and C. 
longa (CL) crude extracts on hepatic levels of CYP2E1 in rats at the end of the 
experiment. Data were expressed as mean ± SEM. Means among groups (n = 6 
rats/group) show significant difference, **P<0.01 compared with the normal 
control group. *P<0.01 compared with cirrhosis control group. No significant 
difference was observed between the low dose CL and high dose CL when 
compared with cirrhosis control group. Normal control (distilled water). Cirrhosis 
control (TAA 200 mg/kg). Reference control (Silymarin 50 mg/kg). Low dose BR 
and CL (250 mg/kg). High dose BR and CL (500 mg/kg). 
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Table 4.8: Effect of B. rotunda and C. longa crude extracts treatment on urine level of OHdG and liver tissue homogenate level 
of Nitrotyrosine and MDA from the rats at the end of 8 weeks study. 
 
Group 8-OH-dG  (ng/ml) 
Nitrotyrosine  
(ng/ml) 
MDA  
(nmol/mg protein) 
Normal control 
(10% Tween 20, 
5ml/kg) 
2.17 ± 0.33 1.06 ± 0.07 1.22 ± 0.15 
Cirrhosis control 
(TAA i.p, 200mg/kg) 5.40 ± 0.34** 3.87 ± 0.13** 3.94 ± 0.09** 
Reference control  
(Silymarin 50 mg/kg) 2.80 ± 0.15* 1.67 ± 0.07* 1.94 ± 0.21* 
Low dose B. rotunda 
(250 mg/kg) 3.13 ± 0.37* 2.33 ± 0.24* 2.08 ± 0.04* 
High dose B. rotunda 
(500 mg/kg) 3.07± 0.09* 1.47 ± 0.13* 1.60 ± 0.03* 
Low dose C. longa 
(250 mg/kg) 2.83 ± 0.03* 1.40 ± 0.20* 1.67 ± 0.36* 
High dose C. longa 
(500 mg/kg) 2.37 ± 0.09* 1.33 ± 0.13* 1.29 ± 0.32* 
8-OH-DG; 8-hydroxy deoxy guanosine, MDA; malondialdehyde. Data are expressed as mean ± SEM.  Means among groups (n 
= 6 rats/group) show significant difference. *P<0.001 compared with cirrhosis control group. **P<0.001 compared with the 
normal rats of the control group.
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4.3.8. Liver Antioxidant Enzymes 
The endogenous antioxidant enzymes SOD, CAT.and GPx  were used to indirectly 
measure the loss of hepatocytes in the cirrhotic livers of animals and the results are shown 
in Table. 4.9. SOD, CAT and GPx results were similar to that of the markers of oxidative 
but oppositely, where the rats of the cirrhosis control group recorded lower values of SOD, 
CAT and GPx than in normal rats. The severe damage that happened to the cells of the 
cirrhotic livers explains these results. The treatment of the cirrhotic animals with low and 
high dose B. rotunda extract or C. longa extract significantly (P<0.05) increased the levels 
of SOD, CAT and GPx, and induced the survival of hepatocytes. Collectively, these results 
encourage the suggestion that treatment with either plant extract could provide a favorable 
protection of the hepatocytes from further damage. 
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Table 4.9: Effect of B. rotunda and C. longa crude extracts treatment on the liver tissue homogenate level of SOD, CAT and 
GPx from the rats at the end of 8 weeks study. 
   
Group SOD  (U/mg protein) 
CAT  
(nmol/min/mg protein) 
GPx  
(nmol/min/mg protein) 
Normal control 
(10% Tween 20, 5ml/kg) 14.89 ± 0.28 54.00 ± 0.36 860.37 ± 19.32 
Cirrhosis control 
(TAA i.p, 200mg/kg) 9.80 ± 0.13** 27.49 ± 1.67** 451.00 ± 89.68
## 
Reference control  
(Silymarin 50 mg/kg) 14.03 ± 0.18* 52.76 ± 3.29* 926.11 ± 36.42* 
Low dose B. rotunda 
(250 mg/kg) 12.03 0.06 
(P=0.51) 41.34 ± 2.74# 902.59 ± 69.09# 
High dose B. rotunda 
(500 mg/kg) 14.17 ± 0.19* 51.42 ± 1.34* 975.05 ± 54.08* 
Low dose C. longa 
(250 mg/kg) 13.70 ± 1.08
# 51.06 ± 1.80* 975.47 ± 26.32* 
High dose C. longa 
(500 mg/kg) 14.77 ± 0.41* 54.07 ± 2.06* 1011.80 ± 46.84* 
SOD: superoxide dismutase, CAT: catalase, GPx: glutathione peroxidase. Data are expressed as mean ± SEM.  Means among 
groups (n = 6 rats/group) show significant difference. *P<0.001 compared with cirrhosis control group. **P<0.001 compared 
with normal control group. #P<0.01 compared with cirrhosis control group. ##P<0.01 compared with normal control group.
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4.3.9. Cytokines and Chemokines Assessment  
The serum level of TGF-β1 and the serum levels of NF-ĸB and IL-6 from the 
samples collected from all sacrificed rats are shown in Figure 4.11. The serum level of 
TGF-β1 and the levels of hepatic NF-ĸB and IL-6 were significantly elevated (P<0.05) in 
the samples from cirrhosis control group (100.00 ± 10.00 pg/ml, 2.86 ± 0.06 ng/ml and 
288.58 ± 11.15 pg/ml respectively) compared to other experimental groups. Treatment of 
animals with of B. rotunda extract, reduced the serum levels of the fibrogenic factor TGF-
β1 to 81.67 ± 1.67 pg/ml and the inflammatory mediators NF-ĸB and IL-6 to 1.93 ± 0.05 
ng/ml and 148.12 ± 15.61 pg/ml respectively in the low dose B. rotunda-treated rats and 
58.33 ± 4.41 pg/ml, 1.43 ± 0.07 ng/ml and 129.50 ± 3.79 respectively in the high dose B. 
rotunda-treated rats. In addition, the serum levels of TGF-β1, NF-ĸB and IL-6  decreased 
to 60.00 ± 5.00 pg/ml, 1.45 ± 0.07 ng/ml and 154.76 ± 19.45 pg/ml respectively in the low 
dose C. longa-treated group and 53.33  ± 1.67 pg/ml, 1.35 ± 0.04 ng/ml and 129.94 ± 18.87 
pg/ml in the high dose C. longa-treated group. Levels of TGF-β, NF-ĸB and IL-6 from the 
high dose of both plant extracts approached the values obtained from the Silymarin-treated 
group (63.33 ± 1.67 pg/ml, 1.49 ± 0.06 ng/ml and 125.35 ± 5.06 pg/ml, respectively) 
compared to the higher values in the low dose from each plant extract. Results suggest that 
both plant extracts have dose-dependent nature in their inhibitory effect to the 
profibrogenic and proinflammatory cytokines and NF-kB chemokine. 
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Figure 4.11: Effect of B. rotunda (BR) and C. longa (CL) crude extracts on the serum 
level of TGF-B1, NF-kB and IL-6 in rats at the end of 8 weeks study. (a) TGF-β1 standard 
curve (b) Effect of BR and CL on TGF-β1 (c) NF-ĸB standard curve (d) Effect of BR and 
CL on NF-ĸB (e) IL-6 standard curve (f) Effect of BR and CL on IL-6. The data were 
analyzed as as Mean ± SEM. Significant difference was noticed between the means of 
groups (n = 5 rats/group), **P<0.001 compared to the normal control group. *P<0.001 
compared to cirrhosis control group #P<0.01 compared to cirrhosis control group. Normal 
control (distilled water). Cirrhosis control (TAA 200 mg/kg). Reference control 
(Silymarin 50 mg/kg). Low dose BR and CL (250 mg/kg). High dose BR and CL (500 
mg/kg). 
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4.3.10. Serum Bax, BcL-2 and Caspase-3 
The level of the pro-apoptotic protein Bax and the anti-apoptotic protein Bcl-2 in 
the rat sera are shown in Figure 4.12c and the ratio of Bax/Bcl-2 is shown in Figure 4.12d. 
Bax results showed no significance between cirrhosis and normal control group rats (1.61 ± 
0.15 and 1.07 ± 0.04 ng/ml respectively). On the other hand, there was significant increase 
(P<0.05) in the level of Bax from silymarin-treated, high dose B. rotunda-treated low dose 
and high dose C. longa-treated groups (4.95 ± 0.11, 4.68 ± 0.19, 4.47 ± 0.15 and 5.43 ± 
0.12 ng/ml respectively) compared to cirrhosis control group. On the contrary, the level of 
anti-apoptotic protein Bcl-2 showed significant increase (P<0.05) in the cirrhosis control 
group compared to normal group (2.57 ± 0.23 and 0.89 ± 0.09 ng/ml respectively), whereas 
no significance observed between any of the treated groups when compared with cirrhosis 
control group indicating enhanced apoptosis in silymarin, B. rotunda and C. longa treated 
groups as confirmed by the ratio Bax/Bcl-2 in Figure 4.12b. Furthermore, the serum level 
of caspase-3 in the cirrhosis control group was not significantly higher (2.11 ± 0.48 ng/ml) 
compared to normal group (1.43 ± 0.33 ng/ml) as illustrated in Figure 4.13. Treating the 
cirrhotic livers with silymarin, high dose B. rotunda, low and high dose C. longa elevated 
the caspase-3 value to reach 5.54 ± 0.27, 5.83 ± 0.19, 5.08 ± 0.08 and 6.58 ± 0.35 ng/ml 
respectively. The similarity observed in the results of Bax and caspase-3 confirms the 
enhancement of apoptosis by both plant extracts in the same manner as the reference drug, 
silymarin.  
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Figure 4.12: (a) Bax standard curve (b) Bcl-2 standard curve (c) Effect of BR and 
CL crude extracts on serum level of the pro-apoptotic protein Bax and the anti-
apoptotic protein Bcl-2 at the end of 8 weeks study (d) Bax/Bcl-2 Ratio. Data were 
expressed as mean ± SEM. *P<0.05 significance compared to the group of cirrhosis 
control. **P<0.05 significance compared to the group of normal rats. Normal control 
(distilled water). Cirrhosis control (Thioacetamide 200 mg/kg), Reference control 
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(Silymarin 50 mg/kg), Low dose BR and CL (250 mg/kg), High dose BR and CL 
(500 mg/kg). 
 
 
 
Figure 4.13: (a) Caspase-3 standard curve (b) Effect of B. rotunda and C. longa 
crude extracts on the serum caspase-3 level at the end of 8 weeks period of 
experiment. Data were expressed as mean ± SEM. *P<0.05 significance compared 
to the group of cirrhosis control. Normal control (distilled water). Cirrhosis control 
(TAA 200 mg/kg), Reference control (Silymarin 50 mg/kg), Low dose BR and CL 
(250 mg/kg), High dose BR and CL (500 mg/kg). 
 
4.3.11. Hepatic MMP-2, MMP-9 and TIMP-1 
The results of the effect of B. rotunda and C. longa extracts treatment on the liver 
tissue homogenate level of MMP-2, MMP-9 and TIMP-1collected from all experimental 
animals are illustrated in Table 4.10. From the results, the level of the tested enzymes were 
significantly high (P<0.05) in the cirrhosis control group rats compared to all other groups. 
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On the other hand, administration of B. rotunda extract to the animals significantly 
(P<0.05) attenuated the enzymatic level of MMP-2, MMP-9 and TIMP-1 to approach the 
values of the reference control group with the exception of the low dose B. rotunda group 
which didn’t show significance to cirrhosis control group in MMP-2 indicating the efficacy 
of the plant extract treatment in a dose-dependent manner. Furthermore, Oral 
administration of low and high doses of C. longa-treated animals reduced the level of 
MMP-9 in their liver homogenates, to approach the values of silymarin-treated group, but 
didn’t show significant effect on the level of MMP-2 and TIMP-1. These results 
recommend B. rotunda more than C. longa treatment in inhibiting extracellular matrix 
deposition in the rat livers via down-regulation of MMP-2, MMP-9 and TIMP-1.  
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Table 4.10: Effect of B. rotunda and C. longa extracts treatment on the liver tissue homogenate level of MMP-2, MMP-9 and 
TIMP-1 from the rats at the end of 8 weeks study. 
   
Group MMP-2  (ng/ml) 
MMP-9  
(ng/ml) 
TIMP-1  
(ng/ml) 
Normal control 
(10% Tween 20, 5ml/kg) 2.65 ± 1.07 9.01 ± 2.34 1.42 ± 0.55 
Cirrhosis control 
(TAA i.p, 200mg/kg) 8.43 ± 0.86** 45.61 ± 1.88** 6.09 ± 1.35** 
Reference control  
(Silymarin 50 mg/kg) 3.34 ± 0.13* 16.72 ± 2.43* 1.77 ± 0.06* 
Low dose B. rotunda 
(250 mg/kg) 5.86 ± 0.26 30.21 ± 4.43* 2.06 ± 0.19* 
High dose B. rotunda 
(500 mg/kg) 3.86 ± 0.69* 14.80 ± 2.30* 1.82 ± 0.05* 
Low dose C. longa 
(250 mg/kg) 6.40 ± 0.66 21.14 ± 4.29* 3.98 ± 0.16 
High dose C. longa 
(500 mg/kg) 6.92 ± 0.16 13.46 ± 3.16* 3.89 ± 0.67 
MMP-2; matrix metalloproteinase-2, MMP-9; matrix metalloproteinase-9, TIMP-1; metalloproteinase inhibitor-1. Data are 
expressed as mean ± SEM. Means among groups (n = 6 rats/group) show significant difference. *P<0.05 compared to cirrhosis 
control group. **P<0.05 compared with normal control group.
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4.3.12. Immunohistochemistry of Bax, Bcl2 and PCNA 
Bax, Bcl2 and PCNA staining of hepatic cells of all rats are shown in Figures. 
(4.14a and b, and 4.15). Hepatocytes of liver tissues from cirrhosis control group rats 
showed down-regulation of Bax staining with up-regulation of Bcl2-positive hepatocytes 
and more PCNA staining indicating severe necrosis with high cell proliferation to repair the 
damaged hepatocytes. Hepatocytes from Silymarin-treated rats showed up-regulated Bax 
expression, down-regulated Bcl2 expression and few PCNA staining indicating lower 
levels of proliferation to regenerate the necrotized hepatocytes and more apoptosis than 
necrosis. Liver tissues treated with low dose and high dose B. rotunda and C. longa extracts 
induced hepatocyte apoptosis and shifted necrosis to apoptosis as indicated by up-regulated 
Bax expression, down-regulated Bcl2 and down-regulated cell proliferation as indicated by 
reduced PCNA staining. These findings support the idea of B. rotunda and C. longa 
extract-induced hepatoprotective activities against progressive liver damage by increasing 
apoptosis and ameliorating cell proliferation. 
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Figure 4.14: Immunohistochemistry staining of Bax and Bcl2 of representative livers 
sampled from rats in different experimental groups. (ia) Less apoptosis indicated by few 
Bax-positive hepatocytes (white arrow) and (ib) more Bcl2-positive hepatocytes (black 
arrow) in liver tissues from a cirrhosis control rat. (iia) High numbers of Bax-positive 
iv iv 
v v 
vi vi 
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hepatocytes (White arrow) and (iib) very less Bcl2-positive hepatocytes (black arrow) 
noticed in the liver from a hepatoprotected rat treated with Silymarin. (iiia, va) Moderate 
Bax staining (white arrow) indicating moderate apoptosis and (iiib, vb) moderate Bcl2 
staining (black arrow) indicating moderate apoptosis in the liver from the rats treated with 
low dose B. rotunda (BR) and C. longa (CL) extracts respectively. (iva, via) High numbers 
of Bax-positive cells (white arrow) with severe apoptosis and (ivb, vib) very less Bcl2-
positive hepatocytes (black arrow) were observed in the liver of the  rats treated with high 
dose B. rotunda (BR) and C. longa (CL) extracts respectively (Original magnification ×40). 
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Figure 4.15: Immunohistochemistry staning of PCNA of liver tissue samples of rats in the 
different groups of the experiment. (a) Normal livers showed absence of PCNA expression 
in hepatocytes of the normal control group. (b) Cirrhosis control liver showed high degree 
of fibrosis associated with high PCNA expression in the necrotized hepatocytes. (c) 
Silymarin-treated liver showed less PCNA-stained hepatocytes (arrow) indicating less 
hepatocyte proliferation. (d, f) The low dose BR and low dose CL-treated liver respectively 
showed moderate hepatocyte proliferation as indicated by moderate PCNA staining (arrow) 
in the hepatocytes. (e, g) High dose BR and High dose CL-treated livers respectively 
showed minor PCNA expression (arrow) with few proliferated hepatocytes was observed in 
the liver. (Original magnification ×40). 
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4.4. Isolation of Panduratin A and Germacrone Compounds from their 
Ethanolic Crude Extracts 
4.4.1 Isolation of Panduratin A from B. rotunda extract  
Dry pack column chromatography of B. rotunda crude extract resulted in 11 
fractions as shown in (Table 4.11). The results of TLC of all fractions versus Panduratin A 
compound showed that fraction BR-3 contained panduratin A (Figure 4.16a and b) 
recording a retardation factor similar to that of Panduratin A standard (Rf = 0.29). These 
results were also confirmed by High performance liquid chromatography (Figure 4.17a and 
b). LCMS chromatogram of the isolated Panduratin A is illustrated in Figure 18a and c 
showing that the compound was detected at m/z 407.2211. 
 
 4.4.2 Isolation of Germacrone from C. longa extract  
Dry-pack column chromatography of C. longa crude extract resulted in 18 fractions 
as illustrated in (Figure 3.2). TLC screening of all the resulting fractions showed that 
fractions CL-1-4 might contain germacrone compound when compared to TLC from the 
Germacrone standard (Rf = 0.41). Column chromatography for the combined fractions CL-
1-4 resulted in 21 fractions (Table 4.12) TLC screening for the resulting fractions versus 
germacrone standard showed that fraction CL-1-4-7 and CL-1-4-13 might contain 
germacrone (Figure 4.19). HPLC profiling of both fractions versus germacrone standard 
confirmed that fraction CL-1-4-13 contained the target compound (Figure 4.20). LCMS of 
the isolated germacrone showed that the compound was detected at m/z 219.1740 (Figure 
4.21).   
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 Table 4.11: The % yield of the fractions obtained from dry pack column chromatography. 
Fraction Solvent system (%) 
Volume of solvent (ml) 
(Approx. value) 
Weight of tube 
(g) 
Weight of tube+ 
sample (g) 
Weight of 
sample (mg) 
Yield 
% 
BR-(1) 95 Hex: 5 Ea 125 x3 5.3340 5.5070 173 6.48 
BR-(2) 90 Hex: 10 Ea 125 5.2983 5.3269 28 1.05 
BR-(3) 85 Hex: 15 Ea 125 5.3866 6.1537 767.1 28.73 
BR-(4) 80 Hex: 20 Ea 125 5.2738 6.0316 757.8 28.38 
BR-(5) 75 Hex: 25 Ea 125 5.1593 5.4257 266.4 9.98 
BR-(6) 70 Hex: 30 Ea 125 5.2910 5.3991 108.1 4.04 
BR-(7) 65 Hex: 35 Ea 125 5.2428 5.3898 147 5.5 
BR-(8) 60 Hex: 40 Ea 125 5.2033 5.3147 114 4.27 
BR-(9) 55 Hex: 45 Ea 125 5.2586 5.3831 124.5 4.66 
BR-(10) 50 Hex: 50 Ea 125 5.2013 5.2909 89.6 3.36 
BR-(11) 100 Ea 125 x2 5.2434 5.4131 169.7 6.30 
Total weight= 2.74 g. % yield = 2.74/ 2.67 = 102.6 %. 
B. rotunda (BR) crude (2.67 g) 
(Silica gel column)
Dry-Pack CC 
BR1 
95:5  
H: EA
BR2 
9:1    
H: EA
BR3 
99:1 
H:EA
BR4 
99:1 
H:EA
BR5 
99:1 
H:EA
BR6 
99:1 
H:EA
BR7 
99:1 
H:EA
BR8 
99:1 
H:EA
BR9 
99:1 
H:EA
BR10 
99:1 
H:EA
BR11 
99:1 
H:EA
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Solvent front 
BR-3 High concentration  
   Panduratin A standard 
  BR-3 Low concentration 
    2cm  Rf=2/7 
 
 
 
 
Figure 4.16: TLC of fraction BR-3 versus Panduratin A standard. (a) TLC before 
UV. (b) TLC after UV. (c) Pure crystals (96.6%) of isolated Panduratin A. 
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Baseline 
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Figure 4.17: HPLC profile of (a) BR-3 (20 mg/ml) showing Panduratin A compound, (b) Panduratin A standard (10 mg/ml). 
a 
Panduratin A 
Rt =10.000 
b 
Panduratin A 
Rt =10.004 
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Figure 4.18: (a) LCMS of fraction BR-3. (b) Panduratin A structure according to PubChem library. (c) Mass spectrum of 
Panduratin A. 
Fragmentor Voltage 125 Collision Energy 0 Ionization Mode ESI
6x10
0
1
2
3
4
5
6
Counts vs. Acquisition Time (min)
8.5 9 9.5 10 10.5 11 11.5 12 12.5 13
+ESI TCC Scan Frag=125.0V TKPA-2_65mgml-MS-Pos-15_30.d  
b 
c 
a 
Panduratin A 
C26H30O4 
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 Table 4.12: The % yield of the sub-fractions obtained from dry pack column chromatography of the combined fraction CL-1-4 
Fraction Solvent system (%) 
Volume of 
solvent (ml) 
 (Approx. 
value) 
Weight of tube 
(g) 
Weight of tube+ 
sample 
 (g) 
Weight of 
sample  
(mg) 
Yield 
% 
CL1-4-(1)  100 Hex 200 5.1430 5.2235 80.5 0.84 
CL1-4-(2)  100 Hex 10 5.1370 5.1407 3.7 0.04 
CL1-4-(3)  100 Hex 10 5.1673 5.2273 60.0 0.63 
CL1-4-(4)  100 Hex 10 5.1894 5.2620 72.6 0.76 
CL1-4-(5)  100 Hex 10 5.1185 5.1205 2.0 0.02 
CL1-4-(6)  95 Hex : 5 Ea 10 5.1141 5.1942 80.1 0.84 
CL1-4-(7)  95 Hex : 5 Ea 10 5.2967 5.3559 59.2 0.62 
CL1-4-(8)  95 Hex : 5 Ea 10 5.1613 5.2089 47.6 0.50 
CL1-4-(9)  95 Hex : 5 Ea 10 5.2877 5.3424 54.7 0.58 
CL1-4-(10)  95 Hex : 5 Ea 10 5.3103 5.4989 188.6 1.99 
CL1-4-(11)  95 Hex : 5 Ea 10 5.1465 5.4311 284.6 3.00 
CL1-4-(12)  95 Hex : 5 Ea 10 5.2431 5.3053 62.2 0.65 
CL1-4-(13)  95 Hex : 5 Ea 10 5.2010 5.6434 442.4 4.70 
CL1-4-(14)  95 Hex : 5 Ea 10 5.1465 5.5906 444.1 4.70 
CL1-4-(15)  95 Hex : 5 Ea 10 5.1611 5.2305 69.4 0.73 
CL1-4-(16)  95 Hex : 5 Ea 10 5.2039 5.2347 30.8 0.03 
CL1-4-(17)  95 Hex : 5 Ea 10 5.2111 5.2367 25.6 0.27 
CL1-4-(18)  95 Hex : 5 Ea 10 5.1342 5.1691 34.9 0.37 
CL1-4-(19)  95 Hex : 5 Ea 10 5.1897 5.1915 1.8 0.02 
CL1-4-(20)     95 Hex : 5 Ea 100 5.1767 5.1930 16.3 0.17 
CL1-4-(21)    80 Hex : 20 Ea 100 5.1699 5.4554 285.5 3.00 
Total weight of sample = 2.3466 g % yield= 2.3/ 9.5 x 100%= 24.7% 
116 
 
  
Figure 4.19: TLC of fraction CL-1-4 -7 and CL-1-4-13 versus Germacrone standard. (a) TLC before UV. (b) TLC after UV. 
Rf = 0.41 3.2 cm 
7.7 cm Germacrone standard 
a 
Germacrone standard 
b 
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Figure 4.20: HPLC profile of (a) Fraction CL-1-7 (20 mg/ml) (b) Fraction CL-1-13 (20 mg/ml) (c) Germacrone standard (1mg/ml). 
a 
b Germacrone 
c 
Germacrone standard 
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Figure 4.21: (a) LCMS of fraction CL-1-13 after 3 times collection from its HPLC. (b) Germacrone structure according to 
PubChem library.(c) Mass spectrum of Germacrone.
Fragmentor Voltage 125 Collision Energy 0 Ionization Mode ESI
4x10
0
1
2
3
4
5
Counts vs. Acquisition Time (min)
7 7.05 7.1 7.15 7.2 7.25 7.3 7.35 7.4 7.45
+ESI TCC Scan Frag=125.0V CLG-60ppm-MS-Pos-15_30.d  
b a Germacrone 
C15H22O 
c 
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4.5. DPPH Scavenging Activity of Panduratin A 
Panduratin A compound exhibited comparable free radical scavenging activity for 
DPPH compared to that of Ascorbic acid (AC) as shown in Figure 4.22. At the highest 
tested concentrations 100 µg/ml, the DPPH inhibition % of PA was significantly (P<0.001) 
lower than that of the standard AC and the reference drug SI. On the other hand, at the 
lowest tested concentration 1 µg/ml, there was no significance between PA and the 
standards AC or between PA and the standard drug SI. The medium concentration 10 
µg/ml revealed low significance (P<0.001) between PA and the standards AC, while the 
significance detected between PA and SI was P = 0.52. These results indicated that PA had 
less potent radical scavenging effect and antioxidant activity than AC, but similar to that of 
the reference drug SI at the low and medium concentrations 1 and 10 µg/ml, but no 
significance at the high concentration 100 µg/ml. 
 
 
 
 
120 
 
  
Figure 4.22: (a) Ascorbic acid standard curve. (b) % inhibition of DPPH scavenging 
activity of Panduratin A compound (PA) compared with the standard Ascorbic acid (AC) 
and the reference drug Silymarin (SI). *P<0.001compared to AC10/AC100. 
#P<0.001compared to SI100. ##P=0.52compared to SI10. 
 
4.6. In Vitro Protective Activity of Panduratin A and Germacrone compounds 
against TAA-cytotoxicity 
4.6.1. IC50 of TAA 
The percentage cell viability of WRL-68 cells after being incubated with different 
concentrations of TAA (0.03, 0.04 and 0.05 g/ml) for 30, 60, 90 and 120 min, are 
illustrated on Figure 4.23. Results showed that incubating the cells with the mentioned 
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TAA concentrations decreased the cell viability gradually with time from 86.10 ± 0.36, 
81.67 ± 1.26 and 83.74 ± 3.60 % respectively after 30 minutes of incubation reaching 42.94 
± 1.35, 44.77 ± 1.93 and 37.33 ± 2.19% respectively after 120 minutes of incubation. 
Furthermore, the % cell viability recorded 51.17 ± 1.49 % after 60 minutes of incubation 
with TAA 0.04 g/ml compared with 61.33 ± 1.86 % for the lower tested dose of TAA (0.03 
g/ml) and 44.14 ± 2.13 % for the higher tested dose of TAA (0.05 g/ml) indicating that the 
IC50 of TAA is 0.04 g/ml. 
 
 
Figure 4.23: IC50 of TAA, data were presentd in the form of Mean ± SEM. *P<0.05 
compared to TAA-treated cells (0.03 g/ml) and #P<0.001 compared with TAA-treated cell 
(0.04 g/ml). D.W: distilled water; TAA: thioacetamide. 
 
 
4.6.2. Cytotoxicity Effect of Panduratin A and Germacrone compounds in WRL-68 
Cytotoxicity screening of the tested concentrations of Panduratin A (PA) and 
Germacrone (GE) compounds in WRL-68 showed that both compounds were not cytotoxic 
even at the highest tested concentration 100 µg/ml. In addition, results showed that no 
significance between the various groups as shown in Figure 4.24. 
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 Figure 4.24: Cytotoxicity test of different concentrations of Panduratin A (PA) and 
Germacrone (GE) compounds on WRL-68 cell line. Data were presented in the form of 
Mean ± SEM. No significance between the treated and the control group 2.5% dimethyl 
sulphoxide (DMSO). SI1: 1 μg/ml, SI10: 10 μg/ml, SI100: 100 μg/ml, PA1: Panduratin A 
1μg/ml, PA10: 10 μg/ml, PA100: 100 μg/ml. 
 
 
4.6.3. Protective Effect of Panduratin A and Germacrone Treatment on Cell Viability 
The results of treating WRL-68 cells with different concentrations of Panduratin A 
and Germacrone compounds after inducing TAA-cytotoxicty are shown in Figure 4.25. 
Results revealed that cell viability decreased dramatically in the toxin control cells from 
24.67 ± 1.20 % after 24 hours of incubation to reach 5.33 ± 2.03 % after 72 hours of 
incubation. Treatment of the injured cells with PA10 (10 μg/ml) significantly improved 
(P<0.05) the cell viability from 55.00 ± 2.65% after 24 hours of incubation to 75.67 ±1.45 
% after 72 hours of incubation approaching the values of SI10 treatment (10 μg/ml) 52.67 ± 
3.38 %  after 24 hours of incubation and 78.00 ± 1.15 after 72 hours of incubation. 
Moreover, treatment of the cells with PA100 and GE100 (100 μg/ml) improved the cell 
viability from 61.00 ± 1.15 and 56.67 ± 1.86% respectively after 24 hours of incubation to 
83.63 ± 1.16 % and 77.97 ± 2.65 % respectively after 72 hours of incubation approaching 
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the values recorded from the reference compound SI100-treated cells 64.00 ± 3.21 % after 
24 hours of incubation and 82.18 ± 1.41 % after 72 hours of incubation. Besides, PA1, GE1 
and GE10-treated cells did not show significant improvement in the cell viability 
suggesting that the protective effect of Panduratin A and Germacrone compounds is dose-
dependent. 
 
Figure 4.25: Effect of Panduratin A (PA) and Germacrone (GE) compounds on the cell 
viability after 24, 48 and 72 hours of incubation with different concentrations of the 
compounds compared to the reference drug silymarin (SI). Data were presented in the form 
of Mean ± SEM. *P<0.05 compared to toxin control (0.04 g/ml). #P<0.05 compared to 
normal control (2.5% DMSO). SI1: 1 μg/ml, SI10: 10 μg/ml, SI100: 100 μg/ml, PA1: 
Panduratin A 1μg/ml, PA10: 10 μg/ml, PA100: 100 μg/ml. 
 
 
 
4.6.4. MDA and SOD Assessments 
Following the oxidative damage caused by incubating the cells with 0.04 g/ml TAA, MDA 
significantly increased (P<0.05) in the cell lysates collected from the cells of the toxin 
control group to (18.11 ± 2.21 nmol/ml) compared to normal control group cells (3.70 ± 
0.70 nmol/ml) as shown in Figure 4.26. Treatment of cells with the medium dose (SI10) 
and the high dose (SI100) of silymarin reduced significantly (P<0.05) the level of MDA in 
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the cell lysates collected from their cells to 9.00 ± 0.58 and 5.67 ± 1.45 nmol/ml 
respectively compared to the toxin control group cells. In the same manner, the high dose 
PA100 and GE100 (100 μg/ml) significantly reduced the level of MDA to 7.33 ± 1.45 and 
7.00 ± 1.15 nmol/ml respectively. Treatment of the cells with the medium dose (10 μg/ml) 
showed significant decrease in MDA level in PA10 group cells (9.11 ± 2.31 nmol/ml) 
compared to toxin control cells, but not in GE10 group cells. Conversely, the high dose of 
SI, PA and GE (100 μg/ml) increased the level of SOD to 2.52 ± 0.46, 2.12 ± 0.14 and 1.87 
± 0.15 nmol/ml respectively compared to the low level of the toxin control group (0.49 ± 
0.22 nmol/ml). The results suggest that Panduratin A and Germacrone compounds may 
protect the liver cells from TAA-induced oxidative damage. 
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Figure 4.26: (a) Malondialdehyde standard curve. (b) SOD standard curve. (c) Effect of 
Panduratin A (PA) and Germacrone (GE) compounds on the level of MDA and SOD in the 
cell lysates collected from all cell groups after 72 hours of incubation with TAA and 
different concentrations of the compounds (1,10 and 100 μg/ml) in parallel with the 
reference drug silymarin (SI). Data were presented in the form of Mean ± SEM. *P<0.05 
compared with to toxin control (0.04 g/ml). #P<0.05 compared to normal control (2.5% 
DMSO). SI1: 1 μg/ml, SI10: 10 μg/ml, SI100: 100 μg/ml, PA1: Panduratin A 1μg/ml, 
PA10: 10 μg/ml, PA100: 100 μg/ml. 
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4.7. In Vivo Hepatoprotective activity of The isolated Panduratin A (PA) 
agianst TAA-Induced Liver Damage in Rats 
 
4.7.1. Acute toxicity 
All the rats in the acute toxicity experiment stayed in existence and did not expose 
death rate or any noticeable toxicity symptoms throughout the 14 days study at the high 
dose of 500 mg/kg. The physical results indicated no symptoms and no changes observed 
in their furs, eyes and mucous walls, habits, shaking, salivations, diarrhea situations and 
snoozes. The body weight of the treated male and female rats increased progressively but 
were not significantly different as compared to those of the control group rats (Table 4.13) 
Serum biochemical parameters recorded the metabolism of normal kidney and liver, and 
the histopathological assessments of the renal and the liver tissues showed no significant 
variations between the control and experimental groups, as shown by the quantitative 
information in Tables 4.14 and 4.15, and Figure 4.27. 
 
Table 4.13: Effect of Panduratin A on the initial and the final body weights of rats 
measured from the acute toxicity test. 
Dose 
Body weight on 
day 0  
(g) 
Body weight on 
day 15  
(g) 
Vehicle (10% Tween 20) 204 ± 10.1 245 ± 10.61 
Low Dose (50 mg/kg) 205 ± 9.93 246 ± 13.07 
High Dose (500 mg/kg) 199 ± 5.02 239 ± 8.12 
The values were expressed as mean ± SEM. There were no significant differences between 
the groups. Significant value was at P<0.05. 
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Table 4.14: Effect of Panduratin A (PA) on the renal function measured from the acute toxicity test on rats. 
Dose Sodium Pottasium Chloride Urea Creatinine 
(mmol/L) (mmol/L) (mmol/L) (mmol/L) (µmol/L) 
Vehicle 
 (10% Tween 20) 139.33 ± 0.24 5.96 ± 0.05 103.98 ± 0.05 6.07 ± 0.03 47.13 ± 0.02 
Low Dose PA 
 (50 mg/kg) 140.02 ± 0.26 6.00 ± 0.03 103.98 ± 0.08 6.14 ± 0.02 47.11 ± 0.03 
High Dose PA 
(500 mg/kg) 139.76 ± 0.31 5.95 ± 0.03 103.94 ± 0.10 6.11 ± 0.02 47.15 ± 0.02 
Values were expressed as mean ± SEM.  There were no significant differences between PA-treated groups and the 
vehicle group. Significant value was at P<0.05. 
 
Table 4.15: Effect of Panduratin A (PA) on the liver function measured from the acute toxicity test on rats. 
Dose 
Total 
protein Albumin Globulin AP ALT AST GGT 
(g/L) (g/L) (g/L) (IU/L) (IU/L) (IU/L) (IU/L) 
Vehicle  
(10% Tween 20) 70.98 ± 0.08 10.85 ± 0.05 60.13 ± 0.08 133.345 ± 0.14 48.78 ± 0.15 154.01 ± 0.05 4.10 ± 0.01 
Low Dose PA  
(50 mg/kg) 71.25 ± 0.20 10.85 ± 0.05 60.40 ± 0.23 133.23 ± 0.17 48.99 ± 0.19 154.02 ± 0.11 4.12 ± 0.01 
High Dose PA 
 (500 mg/kg)  70.81 ± 0.10 10.73 ± 0.05 60.08 ± 0.05 133.08 ± 0.20 48.98 ± 0.05 153.96 ± 0.06 4.10 ± 0.01 
Values were expressed as mean ± SEM.  There were no significant differences between PA-treated groups and the 
vehicle group. Significant value was at P<0.05. 
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Figure 4.27: Histological sections (H&E) of livers (right column) and kidneys (left 
column) obtained from the rats in the acute toxicity test. Rat with the kidney and liver 
shown in (a) and (b) was treated with 5 ml/kg vehicle (10% Tween 20). Rat with the 
kidney and liver shown in (c) and (d) was treated with 5 mg/kg (5 ml/kg) dose of the 
isolated Panduratin A (PA) compound.  Rat with the kidney and liver shown in (e) and (f) 
 a  b 
 c  d 
 e  f 
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was treated with 500 mg/kg (5 ml/kg) dose of the PA compound. There was no significant 
difference in the structures of the liver and kidney between the treatment and control 
groups. (Original magnification x20) 
 
4.7.2. In Vivo Hepatoprotective Activity of PA against TAA-Induced Liver Damage in Rats 
4.7.2.1. Body Weight and Liver Index 
The total body weight of each rat was measured prior to the sacrifice. Similarly, the 
liver weighted after being excised (Table 4.16). The normal control rats followed normal 
growth pattern and attained normal weight gains from about 210.17 ± 11.39 g to 330.00 ± 
10.43 g in 4 weeks. The injection of TAA made the rats hepatotoxic and suffered growth 
retardation as they weighted significantly less than those measured from the other groups. 
When the body weights were factored in, the cirrhotic rats in cirrhosis control group had 
the highest liver index. The rats of silymarin-treated and HDPA-treated groups attained 
body weights as equivalent as the normal rats (Table 4.16). Figure 4.28 showed that the 
weight gain in HDPA (50 mg/kg) and silymarin-treated rats (46.79 ± 1.76 and 46.25 ± 2.51 
% respectively) was significantly high compared to cirrhosis control group (33.75 ± 4.64 
%). The rats of LDPA (5 mg/kg) and MDPA (10 mg/kg) treated animals had better weight 
gain (35.31 ± 2.38 and 45.14 ± 1.55 % respectively) than those of cirrhosis control group, 
but not as much as those attained in the silymarin and the HDPA-treated animals. These 
findings implied that the outcome of the treatment was susceptible to the administered dose 
amount, but the PA at this high dose appeared to be optimal since it was as effective as 
silymarin in counteracting the progression of liver damage.  
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Table 4.16: Effect of Panduratin A (PA) on the measurements results of liver index of the 
rats after the 8 week study against TAA toxicity. 
Treatment Initial body weight (g) 
Final Body 
weight (g) 
Liver weight 
(g) 
Liver index 
(%) 
Normal control 210.17 ± 11.39 330.00 ± 10.43 8.74 ± 0.25 2.67 ± 0.14 
Cirrhosis control 185.00 ± 13.99 244.33 ± 12.56** 9.93 ± 0.36** 4.09 ± 0.14** 
Reference control 
(Silymarin 50 
mg/kg) 
219.00 ± 12.32 318.83 ± 13.04* 8.93 ± 0.35 2.80 ± 0.04* 
LDPA                
(5 mg/kg) 212.00 ± 9.28 258.83 ± 7.93 8.92 ± 0.27 3.32 ± 0.13* 
MDPA             
(10 mg/kg) 200.83 ± 4.92 291.33 ± 6.59 8.45 ± 0.13* 2.90 ± 0.05* 
HDPA              
(50 mg/kg) 211.00 ± 12.44 308.83 ± 15.11* 8.28 ± 0.20* 2.70 ± 0.07* 
The data were analyzed as as Mean ± SEM. Significant difference was noticed between 
the means of groups (n = 5 rats/group), silymarin-treated group, low dose, medium dose 
and high dose PA-treated groups. *P<0.05 compared to cirrhosis control group. **P<0.05 
compared to the normal control group. 
 
 
Figure 4.28: Effect of Panduratin A (PA) on % body weight increase measured from the rats 
at the end of the 8 week study against TAA toxicity.Data were expressed as Mean ± SEM. 
Means among groups (n = 5 rats/group) show significant difference, *P<0.05 compared to 
cirrhosis control group. **P<0.05 compared with the normal control group. #P=0.52 
compared to the group of cirrhosis control. Normal control (distilled water). Cirrhosis 
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control: (Thioacetamide 200 mg/kg). Reference control (Silymarin 50 mg/kg). LDPA (Low 
Dose Panduratin A 5 mg/kg). MDPA (Medium Dose Panduratin A 10 mg/kg). HDPA 
(High Dose Panduratin A 50 mg/kg). 
 
4.7.3. Biochemical Analysis 
Liver function of all rats was determined by measuring the plasma levels of specific 
liver enzymes, and the results are illustrated in Table 4.17. Data revealed that TAA-induced 
liver damage significantly brought up the levels of specific liver enzymes AP, ALT, AST 
and GGT (P< 0.001) compared to the normal control group. The high dose of PA (50 
mg/kg) given to the animals of HDPA group has led to lower enzymatic levels that were 
much like those of normal control group and the silymarin-treated (50 mg/kg) group, and 
better than the levels obtained from the low dose (LDPA) (5 mg/kg) group and the medium 
dose (MDPA). These results verified that the repercussions of the toxicity induced by TAA 
on the liver function may be efficiently be counterbalanced by the explicit results of the PA 
treatment, but in a dose-dependent way. 
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Table 4.17: Effect of Panduratin A (PA) on the liver enzymes of the rats’ plasma after the 
four weeks period of study against TAA toxicity 
Treatment AP  (IU/L) 
ALT  
(IU/L) 
AST  
(IU/L) 
GGT 
 (IU/L) 
Normal 
control 95.70 ± 2.97 76.33 ± 2.69 137.33 ± 5.25 2.65 ± 0.31 
Cirrhosis 
control 307.77± 17.82** 195.27 ± 26.41** 320.67 ± 35.50** 10.72 ± 0.80** 
Reference 
control 
(Silymarin 
50 mg/kg) 
92.12 ± 4.92* 74.67 ± 6.30* 117.50 ± 7.56* 3.46 ± 0.32* 
LDPA                
(5 mg/kg) 131.59 ± 18.27* 110.83 ± 7.64* 238.33 ± 25.51* 7.31 ± 0.54* 
MDPA             
(10 mg/kg) 106.72 ± 8.09* 97.12 ± 13.21* 188.00 ± 11.85* 5.18 ± 0.55* 
HDPA              
(50 mg/kg) 100.46 ± 6.97* 92.67 ± 7.25* 199.29 ± 15.70* 2.50 ± 0.32* 
AP alkaline phosphatase; ALT alanine transaminase; AST aspartate transaminase; GGT 
gamma-glutamyl transferase. Data are expressed as mean ± SEM. Means among groups (n 
= 5 rats/group) show significant difference. *P<0.001 compared to cirrhosis control group. 
**P<0.001 compared to normal control group.  
 
4.7.4. Parameters of Oxidative Damage 
Oxidative stress parameters measured from all rats (urine 8-OH-dG and liver tissues 
homogenate MDA and nitrotyrosine NT) levels are shown in Figures 4.29 and 4.30. 
Generally, cirrhosis animals intoxicated with TAA only, had significantly (P<0.001) 
increased oxidative damage as indicated by the markers OH-dG, NT and MDA (5.87 ± 
0.30 ng/ml, 3.87 ± 0.13 ng/ml and 22.78 ± 5.05 nmol/mg protein respectively) than normal 
control group ( 1.83 ± 0.07 ng/ml, 0.67 ± 0.07 ng/ml and 7.31 ± 1.79 nmol/mg protein 
respectively) and the other experimental animals. Administration of HDPA had 
significantly reduced (P< 0.01) the level of OH-dG, NT and MDA (2.73 ± 0.03 ng/ml, 1.07 
± 0.27 ng/ml and 10.08 ± 2.83 nmol/mg protein respectively) compared to cirrhosis control 
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group. In addition, there were no significant modifications in the analyzed markers between 
HDPA-treated and Silymarin-treated rats (2.73 ± 0.18 ng/ml, 1.47 ± 0.13 ng/ml and 7.83 ± 
2.62 nmol/mg protein respectively). These results suggested that treatment with PA may 
protect hepatic tissues from further damage during liver injury. 
 
  
 
 
Figure 4.29: (a) 8-OH-dG standard curve (b) Nitrotyrosine standard curve (c) Effect of 
Panduratin A (PA) on the urine level of 8-Hydroxy Deoxy Guanosine (8-OH-dG) and liver 
tissue homogenate level of Nitrotyrosine. Data are expressed as mean ± SEM. **P<0.001 
compared to the normal control group. *P<0.01 compared to cirrhosis control group. 
Normal control (distilled water). Cirrhosis control (TAA 200 mg/kg). Reference control 
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(Silymarin 50 mg/kg). LDPA (Low Dose Panduratin A 5 mg/kg). MDPA (Medium Dose 
Panduratin A 10 mg/kg). HDPA (High Dose Panduratin A 50 mg/kg). 
 
 
 
Figure 4.30: (a) Malondialdehyde standard curve (b) Effect of Panduratin A (PA) on the 
liver tissue homogenate level of Malondialdehyde (MDA). Data are expressed as mean ± 
SEM. **P<0.01 compared to the normal control group. *P<0.01 compared to cirrhosis 
control group. Normal control (distilled water). Cirrhosis control: (TAA 200 mg/kg). 
Reference control (Silymarin 50 mg/kg). LDPA (Low Dose Panduratin A 5 mg/kg). MDPA 
(Medium Dose Panduratin A 10 mg/kg). HDPA (High Dose Panduratin A 50 mg/kg). 
 
4.7.5. Hepatocellular Antioxidant Enzymes 
Hepatocellular loss in the livers of cirrhosis rats was ultimately examined by the 
activity of the endogenous enzymes SOD, CAT and GPx. The outcomes are proven in 
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Figure 4.31. SOD, CAT and GPx in cirrhotic rats (9.46 ± 1.90 U/mg protein, 5.24 ± 1.74 
U/min/mg protein and 73.79 ± 11.95 nmol/min/mg protein respectively) were reduced than 
in normal rats indicating the incident of serious harm in the tissues of cirrhotic livers. 
Treating the cirrhotic livers with the high dose of PA (50 mg/kg) significantly (P<0.01) 
improved the levels of SOD, CAT and GPx (46.26 ± 3.89 U/mg protein, 15.06 ± 1.53 
U/min/mg protein and 744.82 ± 13.42 nmol/min/ mg protein respectively) and promoted 
the hepatocellular survival. Moreover, SOD, CAT and GPx levels in the HDPA-treated rats 
approached that of silymarin-treated animals (41.32 ± 3.90 U/mg protein, 14.55 ± 0.50 
U/min/mg protein and 473.26 ± 47.13 nmol/min/mg protein respectively). On the other 
hand, The LDPA and MDPA-treated rats didn’t show significant increase in these 
endogenous enzymes compared to cirrhosis control group. These outcomes jointly 
reinforced the recommendation that therapy with PA could offer a protective environment 
for hepatocytes from further loss, but in a dose dependent way. 
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Figure 4.31: (a) Superoxide dismutase (SOD) standard curve (b) Effect of Panduratin A 
(PA) on the hepatic SOD (c) Catalase (CAT) standard curve (d) Effect of PA on the hepatic 
CAT (e) GPx standard curve (f) Effect of PA on the hepatic GPx. Data are expressed as 
mean ± SEM. **P<0.05 significance compared to the group of normal control. *P<0.05 
significance compared to the group of cirrhosis control. Normal control (distilled water). 
Cirrhosis control: (Thioacetamide 200 mg/kg). Reference control (Silymarin 50 mg/kg). 
LDPA (Low Dose Panduratin A 5 mg/kg). MDPA (Medium Dose Panduratin A 10 mg/kg). 
HDPA (High Dose Panduratin A 50 mg/kg). 
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4.7.6. Liver Gross and Histopathology 
Liver gross and H&E histology sections obtained from all animal groups are shown 
in Figures.4.32 and 4.33 respectively. Normal group rats showed smooth surfaces and 
absence of nodules confirmed histologically by normal liver architecture. Liver gross from 
the untreated cirrhosis rats showed congested livers combined with numerous micro-
nodules and their histology revealed fibrous septae accompanied by proliferated bile ducts 
and inflammatory cells. Very few micro-nodules with less septae and more normal 
hepatocytes were observed on the livers from silymarin-treated and those of the high dose 
PA-treated rats, HDPA On the other hand, MDPA showed improvement in the micro-
nodules which appeared less than LDPA but not as efficient as HDPA or silymarin-treated 
rats. These visual tests afforded further confirmation that PA can be efficient in protecting 
the liver from further damage in a dose-dependent way. 
 
 
 
 
 
 
 
 
 
 
 a  b 
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Figure 4.32: Macroscopic appearances of liver samples collected from all experimental rats. (a) 
Normal liver had smooth surface. (b) Cirrhotic liver showed several micro-nodules on its surface 
place. (c) Liver from a silymarin-treated rat showed smooth surface with very few micro-nodules. 
(d) Liver from a rat treated with LDPA showed surface with slightly more micro-nodules. (e) Liver 
from a rat treated with MDPA showed very minor micro-nodules on its surface. (f) Liver from a rat 
treated with HDPA showed smooth normal surface.  
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Figure 4.33: Histopathological sections of liver samples from rats of all experimental 
groups. (a) Normal liver architecture from a normal control rat. (b) Structural damage with 
fibrotic septae (black arrow) and necrotic proliferated bile ducts (white arrows) in the liver 
of a cirrhotic rat. (c) Mild inflammation with very less fibrotic septae (black arrow) in the 
liver of a silymarin-treated rat. (d) Slightly preserved hepatocytes with small necrotic area 
and fibrotic septa in the livers of rats treated with LDPA. (e, f) Improved hepatocytes and 
architecture with small necrotic areas in the liver of rats treated with MDPA and HDPA 
respectively. 
 
4.7.7. Massson’s Trichrome Staining 
Fibrosis level of liver samples collected from all experimental animals and 
evaluated by Masson’s Trichrome staining, are illustrated in Figure 4.34. No signs of 
collagen deposition in the liver sample of normal control group. Cirrhotic liver of cirrhosis 
control group rats showed congested central vein surrounded by highly deposited collagen 
fibers indicating high level of fibrosis. Silymarin-treated liver showed very low level of 
fibrosis indicated by very less collagen fibers deposit. Gradual decrease in the level of 
fibrosis indicated by the gradual decrease in collagen fibers deposition was observed in the 
liver sections obtained from the PA-treated groups rats. Treating the cirrhotic rats with 
MDPA or HDPA reduced effectively collagen deposition around the central vein more than 
 e  f 
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LDPA group rats. This assessment of the level of fibrosis verifies the previous results that 
PA-treatment protected the livers of animals from progressive fibrosis. 
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Figure 4.34: Masson’s trichrome staining of the liver sections collected from all 
experimental groups and stained with Masson’s Trichrome. (a) No signs of collagen 
deposition or fibrosis in the liver sample from normal rats. (b) Increased deposition of 
collagen fibers stained green (black arrow) around congested central vein showing high 
grade of fibrosis in the liver from a cirrhotic rat. (c) Very less deposited collagen and minor 
fibrosis in the liver of a silymarin-treated rat. (d) Moderate grade of deposited collagen 
around the central vein and moderate level of fibrosis in the liver sample from a rat treated 
with LDPA. (e) Less collagen fibers in the liver of a rat treated with MDPA. (f) Very less 
collagen deposition in the liver a rat treated with HDPA. (Original magnification ×20). 
 
4.7.8. Alpha Smooth Muscle Actin (α-SMA) staining 
Alpha smooth muscle staining of liver sections prepared from the rats of all 
experimental groups demonstrating activated hepatic stellate cells is shown in Figure 4.35. 
The α-SMA was missing from the liver from normal group rats. Highly activated hepatic 
stellate cells indicated by the deep staining of α-SMA in the liver from cirrhosis rats of 
cirrhosis control group. The intensity of α-SMA staining was almost absent in the liver of 
silymarin-treated group livers compared to liver sections from the cirrhosis control group. 
Gradual decrease in the intensity of α-SMA staining in the liver sections from the 
experimental rats treated with different doses of PA with very low staining in the medium 
dose PA-treated rats (MDPA) and the high dose PA-treated rats (HDPA) compared to the 
low dose PA-treated rats (LDPA) demonstrating marked decrease in the number of 
activated hepatic stellate cells in the liver of MDPA group and HDPA rats compared to 
those of group LDPA rats. 
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Figure 4.35: Immunohistochemistry staining of alpha smooth muscle actin (α-SMA) of 
liver sections sampled from all experimental groups. (a) Normal liver did not show signs of 
positive α-SMA staining. (b) Dense brown stain with highly expressed α-SMA (black 
arrow) demonstrating highly activated hepatic stellate cells in the liver of a cirrhotic rat. (c) 
Very few positive α-SMA staining in the silymarin-treated liver. (d) Moderate positive 
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staining of α-SMA in the liver from LDPA group. (e) Few positive α-SMA staining in the 
liver from MDPA group. (f) Very few positive α-SMA staining reflecting very few 
activated hepatic stellate cells in the liver from HDPA group. (Original magnification 
x100).
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CHAPTER V 
DISCUSSION AND CONCLUSIONS 
5.1. Discussion 
Clinical and toxicological research has been performed for therapeutic to ensure the 
safety of these plants. During the experimental period on B. rotunda and C. longa plant 
extracts, all animals did not show any abnormal behavioural expression and toxicological 
signs. Histology of liver and kidneys, and serum biochemistry revealed no significant 
differences between groups (Tables 4.2 and 4.3). These results conclude that the extracts 
are safe enough even at the higher doses and have no acute toxicity. 
 (Jing et al., 2010) reported on B.rotunda and its antioxidants properties which may be 
due to its high contents of flavanoids, Quercetin and Kaempferol. (Kumar et al., 2006) 
reported that C. longa extract contains potent antioxidants. In the present study, C. longa 
extract exhibited higher DPPH scavenging power and ferric reducing power more than B. 
rotunda extract, where both plant extracts showed higher total phenolic content. The 
antioxidant activity of C. longa rhizomes could be attributed to its content of the potent 
phenol compounds curcumin and curcuminoids (Kumar, et al., 2006).  
Furthermore, in this study silymarin was used as control to compare the ferric reducing 
power and the total phenol content of the selected plant extracts. Previous studies, 
explained the silymarin efficacy in hepatoprotective with correlation to curcumin the main 
constituent of C. longa extract (Girish et al., 2009). Similarly, the hepatoprotective activity 
of Quercetin, the active flavonoid in B. rotunda extract having the same efficacy of 
Silymarin (Chouhan et al., 2011). 
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Thioacetamide (TAA) is a potent hepatotoxic chemical, that induces in animal, 
cirrhosis etiology i.e anatomically, structurally, and functionally similar to liver cirrhosis in 
humans and with similar values for common biochemical markers (Plonné et al., 2001). 
The liver is an important organ that performs many metabolic activities and any damage 
occurs in the liver is reflected as disturbance in these functions such as leakage of hepatic 
enzymes (Rees et al., 2005). TAA intoxication is accompanied by elevation in the specific 
liver enzymes due to oxidative stress (Roy et al., 2006). In addition, the damage due to 
TAA causes elevation in Prothrombin time and serum albumin (Lin et al., 2010). Recent 
studies recommended the protective effect of antioxidants to the liver status and its 
functions against drug-induced hepatotoxicity (Oz et al., 2005). Our study investigated the 
hepatoprotective effects of B. rotunda and C. longa ethanolic extracts on the development 
of liver cirrhosis induced by the sustained exposure of the rats to intraperitoneal injection of 
200 mg/kg TAA thrice weekly for 8 weeks. The plasma level of total protein was 
significantly reduced in the cirrhosis control group animals compared to normal group 
animals as described in other TAA intoxication models (Alshawsh et al., 2011). Hepatic 
AP, ALT, AST, GGT and LDH were significantly increased in cirrhosis control rats, as 
previously described (Wong et al., 2012). In addition, cirrhosis control group suffered of 
high level of triglycerides, cholesterol and low-density lipoprotein due to TAA toxicity as 
previously reported by Al-Attar, (2012). Further, results showed that daily oral 
administration of B. rotunda and C. longa extracts resulted in significant recovery of liver 
function parameters. Both plant extracts revealed high efficacy in protecting the liver from 
progressive damage as indicated by the protective effect of both extracts on liver markers. 
This improvement of the liver function parameters in B. rotunda and C. longa treated 
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groups compared to cirrhosis control may be attributed to their antioxidant constituents as 
previously reported (Chen, 2010; Shapiro et al., 2005). 
Due to the crucial role played by HSCs in liver fibrosis via their resistance to apoptosis, 
recent treatment strategies of liver diseases is to inhibit their proliferation or induce their 
apoptosis. The biochemical findings of the present study were supported by the gross and 
histopathology results of rat liver tissues (Figures 4.5 and 4.6) showing that livers from B. 
rotunda and C. longa-treated rats had liver architecture very close to normal. In addition, 
Masson’s Trichrome slides revealed minor collagen synthesis upon administration of B. 
rotunda and C. longa extracts to rats treated with TAA. That was probably due to the 
inhibitory effect of the plant extracts to hepatic stellate cell activation. Inhibition of HSC 
activation and down-regulation of collagen-I in the livers treated with B. rotunda and C. 
longa extracts may be due to the activity of polyphenol constituents which have been 
proved to attenuate HSC activity (Wang et al., 2012). 
Thioacetamide is metabolized by cytochrome enzymes (CYP2E1) inside the liver 
microsomes and convert it to a toxic reactive intermediate known as thioacetamide sulphur 
dioxide through oxidation (Kim et al., 2000), inducing hepatotoxicity in experimental 
animals and producing various levels of liver damage (Sadasivan et al., 2006). All 
experimental animals in the present study were tested for CYP2E1 enzyme level in liver 
homogenate tissues (Figure 4.10) and it was found that the efficacy of both plant extracts 
were variable. B. rotunda extract in comparison with Silymarin control was able to inhibit 
metabolism whereas, C. longa had no affect on CYP2E1 enzyme. Previous studies showed 
that, curcumin the active ingredient of C. longa which constitutes 2.5-6% of the plant 
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rhizome constituents has no effect on CYP2E1 (Bruck et al., 2007; Guangwei et al., 2010). 
On the other hand, the inhibitory effect of B. rotunda extract against CYP2E1 may be one 
of the significant factors in hepatoprotective activity by inhibiting the metabolism of TAA 
and blocking the release of ROS that were responsible for inducing damage of hepatocytes 
as explained in recent studies (Karamanakos et al., 2009). 
Free radical like reactive oxygen species (ROS) are produced by the normal cell’s 
metabolism. These free radicals which increase during liver injury by transformation of 
xenobiotics such as CCl4, ethanol and acetaminophen in the liver, play a crucial role in the 
death of hepatocytes (Muriel, 2009). Liver cirrhosis development by TAA was reported to 
be accompanied by multiple mechanisms (Ahmad et al., 2002). For instance, TAA induces 
hepatocyte damage via its metabolite, TASO2, which covalently binds to the bio-molecules 
of liver cells causing lipid peroxidation, protein oxidation and damage of DNA molecule 
(Chilakapati et al., 2007; Djordjević, 2004). This study evaluated the oxidative stress 
markers and observed the degree of liver cells damage. The level of urine 8-OH-dG, 
nitrotyrosine and MDA (Table 4.8) were high in cirrhosis control compared to treated 
groups. This supported the crude extracts’ antioxidants mechanism in down regulating 
ROS, inhibiting DNA damage, and attenuating protein and lipid oxidation (Elaziz et al., 
2010). The ability of both plant extracts to scavenge free radicals suggests their 
hepatoprotective activity through inhibition of the oxidative stress due to TAA toxicity 
(Masalkar & Abhang, 2005). 
Administration of B. rotunda and C. longa extracts to rats in this experiment reduced 
the high levels of cytokines in the rat liver, supporting previous reports on the suppressive 
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effects of curcumin on the transcription of nuclear factor NF-κB binding activity, (Bruck et 
al., 2007) the inflammatory activity of IL-6 (Fu et al., 2008) and the fibrogenic TGF-β1 
expression (Gaedeke et al., 2004). Further, the suppressive activity of B. rotunda to the 
fibrogenic and inflammatory mediators maybe due to the anti-inflammatory and anti-
fibrotic activity of its flavonoid constituents as reported recently (Marcolin et al., 2012)  
Toxins focus on metabolically effective hepatocytes resulting in hepatocyte 
malfunction and the discharge of ROS, fibrogenic and inflamation related mediators. Many 
researchers recommended that part of liver injury induced by TAA and mediated by 
cytokines (Okuyama et al., 2004) (Mehendale, 2005). The free radicals released as the 
consequences of TAA metabolism in liver cells, activate myofibroblasts that secrete 
fibrinogen and growth factors (Bassiouny, et al., 2011). TGF-β1, a prominent pro-
fibrogenic cytokine with anti-proliferative effects that can up-regulate the deposition of 
ECM via hepatic stellate cells activation. The present study detected high level of TGF-β1 
in the cirrhosis control group rats compared to all other groups (Figure 4-11). In addition, 
the pro-inflammatory cytokines IL-6 and NF-ĸB were elevated in cirrhosis group rats due 
to activation of Kupffer cells by TAA-intoxication  indicating a high inflammatory state in 
the cirrhotic liver as suggested in many studies (Reeves & Friedman, 2002),(Gressner et 
al., 2002), (Wu et al., 2010),(Bassiouny, et al., 2011). 
A number of studies have focused on the molecular regulation of apoptosis. One of the 
characteristic features of liver diseases is the death of hepatocytes as a response to 
drug/toxicant-induced liver injury. The mitochondria perform an essential part in the 
control of cell death (Spierings et al., 2005), which generally follows one of two patterns: 
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necrosis and apoptosis as different results of mitochondrial permeabilization (Malhi et al., 
2006). In apoptotic cell death, mitochondrial outer wall permealization is said to be the 
“point of no run” and regulated by panoply of interaction between pro-apoptotic and anti-
apoptotic proteins (Kuwana et al., 2005). Cytotoxic drugs and cellular stress activate the 
mitochondrial apoptotic pathway (Kang & Reynolds, 2009) so that the inhibitors of Bcl-2 
activate caspase-3 initiating apoptosis, whereas inducers of Bcl-2 induce necrosis of cells 
(Emi et al., 2005). In vivo, necrotic death is often associated with extensive damage in the 
tissue resulting in necro-inflammatory response (Choudhury et al., 2012). Following free-
radical and cellular stress, the interaction between the pro-apoptotic Bax and the anti-
apoptotic Bcl-2 leads to the formation of pores in the mitochondria and the discharge of 
cytochrome C, which sequentially triggers caspase-3 through caspase cascade causing 
apoptosis (Kroemer & Martin, 2005). Down-regulation of Bcl-2 and up-regulation of 
caspase-3 leads to apoptosis (Rana, 2008). In addition, over expression of the pro-apoptotic 
protein Bax promotes apoptosis (Wu et al., 2006). Although in some studies, toxicity 
induced by TAA was found to be accompanied by over-expression of Bax protein levels 
and reduction in the anti-apoptotic protein Bcl2 and its translocation into the mitochondria, 
causing apoptosis (Chen et al., 2006) but other studies suggested that the ROS produced 
from thioacetamide bio-transformation, cause centrolobular necrosis (Sarkar & Sil, 2007). 
In the current study, we observed significant increase in the sera level of Bax protein and 
caspase-3 and decrease in Bcl-2 protein in silymarin, B. rotunda and C. longa- treated 
animals compared to cirrhosis group animals as shown in Figures 4.12 and 4.13 This was 
confirmed by the ratio Bax/Bcl-2 (Figures 4.12d) which was high in the treated groups 
compared to cirrhosis group. Moreover, immunohistochemistry staining of Bax and Bcl-2 
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(Figure 4.14) double confirmed the results as indicated by large number of Bax positive-
stained hepatocytes together with few Bcl2 positive-stained hepatocytes in the liver tissues 
of B. rotunda and C. longa -treated animals, and in Silymarin-treated animals compared 
with the cirrhosis control group. Bcl2 over-expression inhibited apoptosis, probably by 
suppressing the discharge of Cytochrome C from the mitochondria (Choudhury 2012). 
These results show that those cells are subjected to apoptosis and the role of some 
antioxidants such as curcumin and curcuminoids (Wang et al., 2012) in inducing apoptosis. 
This explains the enhancing pathway of C. longa and B. rotunda-treatment to apoptosis. 
Furthermore, Daily feeding of animals with B. rotunda and C. longa extracts in parallel 
with TAA injections three times/week for 8 weeks suppressed the proliferation of 
hepatocytes and their regeneration as the results showed significant decrease in PCNA 
staining in the liver sections from the plant extracts-treated groups similar to that in the 
Silymarin-treated group (Figure 4.15). Recent studies reported similar results that curcumin 
the active polyphenol ingredient of C. longa extract has inhibitory effect on hepatocyte 
proliferation (Wang et al., 2012). Treating the animals with the plant extracts inhibited the 
necrotic effect due to thioacetamide administration by modifying necrosis into apoptosis, 
which may be via cytochrome release from mitochondria and caspase activation (Malhi et 
al., 2006). This modification in vivo would scale down the release of inflammatory factors 
that would suppress further damage in the liver.  
In liver fibrosis, there is an imbalance between excess deposition and / or a decrease in 
the extracellular matrix (ECM) removal with consequent scarring damage (Park et al., 
2010). ECM is mainly controlled by matrix metalloproteinases (MMPs), which are a group 
of proteolytic enzymes that are able to degrade the ECM (Abraham et al., 2005; Wang et 
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al., 2005). Tissue inhibitors of metalloproteinases (TIMPs) regulate tightly the activity of 
MMPs (Parsons et al., 2004; Shi & Li 2005). MMP-9 and TIMP-1 were verified as the 
molecular signatures during TAA-induced liver cirrhosis (An et al., 2006). Park, (2010) 
observed that TAA increased MMP-2 expression in the liver tissues of rats and reported 
that the balance of MMPs and TIMPs determines the degree of liver fibrogenesis. In this 
research, administered animals with plants extract affected the level of MMP-2, MMP-9 
and TIMP-1 in the rat livers intoxicated with TAA. In (Table 4.10) results revealed that 
administration of C. longa extract didn’t show any significant inhibition of MMP-2 and 
TIMP-1 to compare with cirrhotic control group. In addition, C. longa extract treatment 
significantly down-regulated the level of MMP-9 in the rat liver. Similar study reported on 
the hepatoprotective effect of curcumin the active antioxidant compound of C. longa 
rhizomes (Bruck et al., 2007). On the other hand, the animals treated with B. rotunda 
showed significant down-regulation in the hepatic level of MMP-2, MMP-9 and TIMP-1 
similar to silymarin reference group. Although, Cheng et al., (2007) reported that curcumin 
inhibited the proliferation of HSCs isolated from normal Sprague Dawley rats via 
enhancement of MMP-2 and MMP-9 activities, but this study, suggested the efficacy of B. 
rotunda and C. longa extracts through the inhibition of kupffer cells activity as indicated by 
the significant inhibitory effect of both plant extracts on cytokines/chemokine mediators 
TGF-β1, IL-6 and NF-kB level in rats serum. Consequently, the low level of these 
mediators might have contributed to HSCs activation and reduced liver injury (Bruck et al., 
2007). Figure 5.1 illustrates the in vivo hepatoprotective results of B. rotunda and c. longa 
extracts in TAA-induced liver injury in rats in the present study. 
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Figure: 5.1: Summary to the in vivo hepatoprotective activity of B. rotunda and C. longa 
extracts 
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 Thioacetamide is a chemical known for its short half life (Chilakapati et al., 2005) and 
was used in many in vitro studies on liver cell line to induce ROS production. ROS release 
enhances lipid peroxidation in the bio-membranes causing cell death through degeneration 
Of DNA and the degeneration of many cell enzymes (Chen et al., 2006; Sarkar & Sil, 
2007). Although normal embryonic liver cell line WRL-68 expresses some hepatocyte-like 
functional characteristics such as liver function enzymes (AP, ALT and AST) (Gutiérrez-
Ruiz et al., 1994), but nevertheless it was used in this study to test in vitro the 
hepatoprotective activity of Panduratin A, an active antioxidant constituent from B. rotunda 
rhizome (Lai et al., 2012) and Germacrone, an active sesquiterpene constituent from C. 
longa rhizomes (Jayaprakasha et al., 2005; You et al., 2005). In the current research, 
cytotoxicity study was conducted in WRL 68 for the active compounds Panduratin A and 
Germacrone. The increase in viable cell counts after 72 hours of incubation up to the tested 
dose (100 µg/ml) indicates that both compounds are safe to use (Figure 4.24). Furthermore, 
both Panduratin A and Germacrone enhanced the increase in cell viability against TAA-
induced cytotoxicity (Figure 4.25), reduced lipid peroxidation (MDA) and elevated SOD 
enzyme level in the cells treated with the compounds (Figure 4.21). The results showed that 
Panduratin A exhibited more capability to protect against TAA in WRL-68 cells compared 
to Germacrone which showed significant protection only at the highest tested dose (100 
µg/ml). The antioxidative activity of Panduratin A can be attributed to its antioxidant 
property (Sohn et al., 2005). Mau et al., (2003) reported that the essential oil constituents of 
Curcuma zedoaria including Germacrone have high DPPH scavenging activity. In addition, 
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recent efficient preparations of three anticancer compounds have been derived from 
Germacrone compound (Barrero et al., 2011).  
 PA was tested for hepatoprotective in vivo over 4 weeks and showed promise as 
potential medicine. One of the sensitive tests in the diagnosis of liver diseases is analysis of 
serum liver enzymes (Zhang et al., 2006). This study showed that the liver enzymes AP, 
ALT, AST and GGT which were elevated due to the damage of the structural integrity of 
the hepatic cells by TAA intoxication were significantly low in the PA- treated animals 
(Table 4.17). Together with the histopathology results, we hypothesize that Panduratin A 
may be able to preserve the normal architecture of the liver from the damaging effects of 
TAA. 
In the present research, assessment of the oxidative damage markers revealed that the 
damage level to hepatocytes due to oxidative stress was elevated in the untreated cirrhosis 
rats as presented by the increased level of 8-OH-dG, nitrotyrosine and MDA (Figure 4.29). 
However, PA-treatment decreased significantly the level of these markers to approach 
normal values and encouragingly close to that of Silymarin-treated animals. These positive 
results may be explained by free-radical scavenging power of the chalcone nature of PA 
(Lai et al., 2012). Moreover, the release of ROS causes parenchymal cell necrosis 
(Sadasivan, et al., 2006) and the up-regulation of pro-inflammatory and fibrogenic 
mediators activating HSCs (Bruck et al., 2007). In this study, α-smooth muscle actin was 
detected in cirrhosis control group by using immunohistochemistry stain compared to other 
groups (Figure 4.35). This indicates the increased activity of HSCs in the cirrhotic livers of 
cirrhosis group rats and the inhibitory effect of Panduratin A to their activity. 
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TAA metabolism may trigger myofibroblasts that discharge fibrinogen and growth 
factors (Bassiouny et al., 2011) such as the profibrogenic cytokine TGF-β1 that can up-
regulate the deposition of extracellular matrix (ECM) (Gressner et al., 2002). Upon 
activation, HSCs acquire a highly proliferative catalog and generate fibrillar collagen 
within the injured liver (Elsharkawy et al., 2005). The present study showed more 
deposition of Collagen-I as detected histologically by Masson’s Trichrome stain in the 
cirrhosis control group rats (Figure 4.34) compared to PA-treated rats. It is noteworthy to 
suggest that PA-treatment interrupted this vicious cycle by its quenching activity as an 
antioxidant (Sohn et al., 2005). 
Hepatocellular anti-oxidant enzymes SOD, CAT and GPx were reported to be reduced 
in TAA-induced hepatotoxicity (Wang et al., 1999). In this experiment, oral administration 
of PA to the cirrhotic rats considerably reduced the TAA-suppressive effect, diminished the 
damage in liver cells and inhibited free radicals by enhancing antioxidants phagoradicals. 
The action of these enzymes at higher levels very close to normal values (Figure 4.31) 
suggests the antioxidative activity of PA as reported by previous studies (Sohn et al., 
2005). Figure 5.2 shows the hepatoprotective effect of B. rotunda extract in comparison to 
that of its active compound PA. 
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 Figure 5.2: A diagram showing the hepatoprotective effect of B. rotunda extract 
compared to its active compound Panduratin A. 
 
5.2. Conclusions 
 Due to their phenolic constituents as Quercetin, Kaemferol and Panduratin A in 
Boesenbergia rotunda and curcumin and curcuminoids in Curcuma longa, both 
plants extracts exhibit high antioxidant properties. 
 Boesenbergia rotunda and Curcuma longa extracts are not toxic even at higher 
doses. 
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 Boesenbergia rotunda and Curcuma longa extracts showed significant 
hepatoprotective activities against TAA-induced liver damage in rats. Therefore 
they can be recommended as a remedy in liver diseases similar to silymarin. 
 Boesenbergia rotunda and Curcuma longa protected the liver from further damage 
by shifting necrosis into apoptosis and suppressing inflammatory mediators. 
 The significant suppressive activity of Boesenbergia rotunda and Curcuma longa to 
the formation of Collagen I in the liver tissues reveals therapeutic effect of both 
plant extracts on HSC activation.  
 Panduratin A and Germacrone exhibited protective activity against TAA-induced 
liver damage in vitro adding new compounds to liver disease therapy. 
 Panduratin A showed hepatoprotective activity against TAA-induced liver in vivo 
damage suggesting a promising remedy in treating liver disease that may challenge 
silymarin in its hepatoprotective activity. 
 The suppressive effect of Panduratin A to the formation of α-SMA in the liver 
tissues of rats reveals direct inhibitory effect of Panduratin A on the activation of 
HSCs following the new therapeutic strategy in treating liver cirrhosis by inhibiting 
HSCs activation. 
5.3. Future Work 
Based on the results of the present study which indicate the efficacy of Boesenbergia 
rotunda and Curcuma longa in protecting the liver from progressive damage via their 
antioxidant and anti-inflammatory activities, more studies need to be conducted on the 
158 
 
HSCs which are the main target for treating liver cirrhosis. The following studies are 
suggested: 
 Evaluating the efficacy of B. rotunda and C. longa extracts on the treatment of 
liver-induced toxicity. 
  Evaluate the effect of Panduratin A on the intrinsic apoptotic mitochondrial 
pathway in HSCs. 
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APPENDIX II 
REAGENTS AND LABORATORY PROTOCOLS 
 
A1. DPPH free radical scavenging assay  
Reagents: 2, 2-diphenyl-1-picrylehydrazyl (C18H12N5O0) solution. Ascorbic acid 
0.001761 g/ml 
 Preparation of reagent was prepared as a standard. The DPPH solution was prepared by 
dissolving 0.001972 g of DPPH in 50 ml of absolute ethanol then stirred until the DPPH 
was completely dissolved. 
 
B1. Total Phenolic Content (TPC) 
Reagents Commercial Folin-Ciocalteu solution Sodium carbonate Gallic acid  
Preparation of reagent  
1- A ratio of (1:10) of Folin-Ciocalteu solution was prepared by diluting 10 ml of it with 90 
ml dH2O in a dark place.  
2- 5.75 g of sodium carbonate was dissolved in 50 ml of dH2O to give a final concentration 
of 0.115 mg/ml.  
3- 0.2 mg/ml of gallic acid solution was prepared and used as the standard solution  
 
C1. Ferric reducing power (FRAP) 
Reagents Iron (II) sulfate hepatohydrate (FeSO4. 7H2O) Sodium acetate trihydrate buffer 
(C2H3O2N9. 3H2O) 2,4,6-tris(2-pyridyl)-s-triazine (TPTZ) 98% FeCl3. 6H2O  
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Preparation of reagents 0.0278 g of FeSO4.7H2O was dissolved in 100 ml dH2O. 0.0775 
g of acetate buffer was dissolved in 25 ml dH2O mixed previously with 0.4 ml glacial 
acetic acid. 
0.00781 g of TPTZ was dissolved in 2.5 ml dH2O mixed previously with 0.1 ml (1M 
HCL). 0.0135g FeCl3. 6H2O was dissolved in 2.5 ml dH2O. The freshly prepared: acetate 
buffer, TPTZ and FeCl3. 6H2O solutions were mixed and vortexed to obtain the ready to 
use FRAP reagent. 
 
D1. Haematoxylin and Eosin Staining 
   (i) Haematoxylin preparation 
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